<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antiseizure medications: Mechanism of action, pharmacology, and adverse effects</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antiseizure medications: Mechanism of action, pharmacology, and adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antiseizure medications: Mechanism of action, pharmacology, and adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven C Schachter, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Garcia, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>While sharing a common property of suppressing seizures, antiseizure medications have many different pharmacologic profiles that are relevant when selecting and prescribing these agents in patients with epilepsy and other conditions. This includes pharmacokinetic properties, propensity for drug-drug interactions, and side effect profiles and toxicities.</p><p>The pharmacology of antiseizure medications is reviewed here. The use of antiseizure medications in a treatment plan for patients with seizures is discussed separately. Risks of antiseizure medications in pregnancy are also discussed separately. (See  <a class="medical medical_review" href="/d/html/2212.html" rel="external">"Initial treatment of epilepsy in adults"</a> and  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults"</a> and  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a>.)</p><p class="headingAnchor" id="H4007298840"><span class="h1">PHARMACOLOGIC PROFILES</span></p><p class="headingAnchor" id="H2677059073"><span class="h2">Mechanisms of action</span><span class="headingEndMark"> — </span>Antiseizure medications are typically grouped by their principal mode of action, although for many drugs, the precise mechanism of action is not known or multiple actions are suspected  (<a class="graphic graphic_table graphicRef71274" href="/d/graphic/71274.html" rel="external">table 1</a>). To some degree, the cellular effects of antiseizure medications are linked with the types of seizures against which they are most effective. An improved understanding of the molecular effects of existing antiseizure medications as well as development of new antiseizure medications that act against novel targets may allow for more rational polytherapy in the future.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that affect voltage-dependent sodium channels</strong> – Alteration of sodium currents is the most common mechanism of action of available antiseizure medications  (<a class="graphic graphic_table graphicRef71274" href="/d/graphic/71274.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that affect calcium currents</strong> – There are three types of calcium channels in neurons, each of which is distinguished by its rate of reactivation and voltage dependency. Low-threshold T-type calcium currents inactivate quickly and have been described in experimental preparations of thalamic relay neurons. These neurons probably are an integral component of the thalamocortical circuits associated with absence seizures, a subtype of generalized seizures associated with brief episodes of staring and a characteristic three-per-second spike and wave pattern on the electroencephalogram (EEG) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">Ethosuximide</a> diminishes T-type calcium currents in thalamic neurons, which are further reduced as membrane potentials become more hyperpolarized. (See <a class="local">'Ethosuximide'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> bind to the auxiliary alpha-2-delta subunit of a voltage-dependent calcium channel, which may inhibit inward calcium currents and attenuate neurotransmitter release. (See <a class="local">'Gabapentin'</a> below and <a class="local">'Pregabalin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that affect GABA activity</strong> – Gamma-aminobutyric acid (GABA) is a neurotransmitter that is widely distributed throughout the central nervous system and exerts postsynaptic inhibition. The GABA(A) receptor complex has binding sites for GABA, benzodiazepines, and <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>. Picrotoxin and other similar proconvulsants bind to the GABA(A) receptor and block chloride channels, thereby preventing postsynaptic inhibition. Thus, reduced GABAergic tone is viewed as proconvulsant, while increasing GABAergic tone generally has an anticonvulsant effect.</p><p></p><p class="bulletIndent1">Synthesis of GABA is dependent upon the enzyme glutamic acid decarboxylase (GAD), which requires <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">pyridoxine</a> as a coenzyme. Pyridoxine-deficient infants lack the capacity to synthesize GABA normally and are prone to seizures. The metabolism of GABA to succinate occurs in presynaptic neurons and glia by means of the mitochondrial enzyme GABA transaminase (GABA-T).</p><p></p><p class="bulletIndent1">Over time, several antiseizure medications have been designed to increase the supply of GABA by lowering GABA metabolism by GABA-T, reducing the reuptake of GABA into neurons and glia, or increasing the production of GABA by GAD. Other antiseizure medications have been designed to imitate the action of GABA, while still others improve endogenous GABA-mediated inhibition.</p><p></p><p class="bulletIndent1">As examples, benzodiazepines bind to the GABA(A) receptor and facilitate the attachment of GABA to its binding site on the receptor. The inhibitory action of endogenous GABA is magnified because benzodiazepines increase the occurrence of chloride channel openings. <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a> also binds to the GABA(A) receptor. <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">Tiagabine</a> is a potent enhancer of GABA action via specific inhibition of GABA reuptake into presynaptic neurons and glia, and <a class="drug drug_general" data-topicid="10115" href="/d/drug information/10115.html" rel="external">vigabatrin</a> is an irreversible inhibitor of GABA-T that raises the concentration of GABA in the central nervous system. (See <a class="local">'Benzodiazepines'</a> below and <a class="local">'Phenobarbital'</a> below and <a class="local">'Tiagabine'</a> below and <a class="local">'Vigabatrin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs that affect the glutamate receptor</strong> – Glutamate is the most prevalent excitatory neurotransmitter. There are two types of glutamate receptors: ionotropic, which form ion channels that are activated by glutamate binding, and metabotropic, which indirectly activate ion channels via the G protein signalling cascade. Two ionotropic glutamate receptors, N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA), are thought to play a role in the generation and spread of seizures [<a href="#rid2">2</a>]. As examples, <a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">perampanel</a> is a noncompetitive AMPA-type glutamate receptor antagonist, and <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a> and <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> are thought to act in part through NMDA antagonism. (See <a class="local">'Perampanel'</a> below and <a class="local">'Felbamate'</a> below and <a class="local">'Topiramate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs with other mechanisms of action</strong> – <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">Levetiracetam</a> and <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">brivaracetam</a> bind to the synaptic vesicle protein SV2A; binding at this site may modulate synaptic transmission through alteration of vesicle fusion. (See <a class="local">'Levetiracetam'</a> below and <a class="local">'Brivaracetam'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> is chemically related to <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and, like gabapentin, it binds to the alpha-2-delta subunit of voltage-gated calcium channels and modulates calcium currents. Pregabalin also modulates the release of several neurotransmitters including glutamate, noradrenaline, and substance P. (See <a class="local">'Pregabalin'</a> below.)</p><p></p><p class="headingAnchor" id="H398874858"><span class="h2">Therapeutic spectrum</span><span class="headingEndMark"> — </span>Some antiseizure medications are used primarily to treat a broad range of seizures types (both focal and generalized onset) while others are used primarily for focal seizures. These are summarized in the table  (<a class="graphic graphic_table graphicRef78021" href="/d/graphic/78021.html" rel="external">table 2</a>).</p><p>For detailed prescribing information, readers should refer to the individual drug information topics within UpToDate. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>. Complete information on US Food and Drug Administration (FDA) labeling for each drug can be accessed using the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fscience-research%2Fbioinformatics-tools%2Ffdalabel-full-text-search-drug-product-labeling&amp;token=IMdkTPwjShZ0l3qxBMG5QAteHI69f3HgTNUs5uh4k8edmwHeth141Xv%2BbYJlHvyTvnag7gCX7gwVmzBuR6ByX2zBO1sQKNbkGTCSUO0%2FjSODsFdgYy%2FC%2FbUDMfhadJwb&amp;TOPIC_ID=2221" target="_blank">FDA searchable database</a>.</p><p class="headingAnchor" id="H61378992"><span class="h2">Newer-generation agents</span><span class="headingEndMark"> — </span>Over the past several decades, the number of available antiseizure medications has more than doubled. Unlike some of the earliest antiseizure medications such as <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, many of the currently available antiseizure medications have simple pharmacokinetics and more limited effects on liver metabolism [<a href="#rid3">3</a>]. This translates into a generally reduced need for serum monitoring, once- or twice-daily dosing for some, fewer drug-drug interactions, and perhaps a lower rate of adverse effects. Despite these advantages, however, there are few data to suggest significant differences in effectiveness among available antiseizure medications.</p><p class="headingAnchor" id="H1134374643"><span class="h1">ANTISEIZURE MEDICATIONS</span></p><p class="headingAnchor" id="H1213233627"><span class="h2">Benzodiazepines</span><span class="headingEndMark"> — </span>Benzodiazepines bind to the GABA(A) receptor and facilitate the attachment of GABA to its binding site on the receptor. The inhibitory action of endogenous GABA is magnified because benzodiazepines increase the occurrence of chloride channel openings. Drugs in this class include <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a>, <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="9286" href="/d/drug information/9286.html" rel="external">clorazepate</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, and <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a>.</p><p><a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">Clobazam</a> (see <a class="local">'Clobazam'</a> below) is used as adjunctive therapy for the treatment of drop seizures in patients with Lennox-Gastaut syndrome (LGS) and is used in other countries outside of the United States for the treatment of focal seizures. <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">Clonazepam</a> (see <a class="local">'Clonazepam'</a> below) is most often used as an adjunctive therapy for myoclonic and atonic seizures. <a class="drug drug_general" data-topicid="9286" href="/d/drug information/9286.html" rel="external">Clorazepate</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, and <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> are effective for those seizure types as well as for focal and generalized tonic-clonic seizures.</p><p><a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">Lorazepam</a>, <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a> (especially rectal or nasal diazepam), and nasal <a class="drug drug_general" data-topicid="9650" href="/d/drug information/9650.html" rel="external">midazolam</a> are typically used as rescue medications for acute repetitive seizures or status epilepticus. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children"</a> and  <a class="medical medical_review" href="/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management"</a>.)</p><p>As a class, the benzodiazepines may be associated with the development of tolerance, limiting their usefulness in the chronic treatment of epilepsy. Side effects include sedation, irritability, ataxia, and depression. Sudden discontinuation of benzodiazepines may lead to withdrawal seizures.</p><p class="headingAnchor" id="H2528280616"><span class="h2">Brivaracetam</span><span class="headingEndMark"> — </span>Like <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">brivaracetam</a> binds to the synaptic vesicle protein synaptic vesicle glycoprotein 2A (SV2A), which has been linked in animal models to epilepsy [<a href="#rid4">4,5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">Brivaracetam</a> is approved as monotherapy or adjunctive therapy for focal-onset seizures in patients one month of age and older.</p><p></p><p class="bulletIndent1">Randomized trials in adults with refractory focal epilepsy have explored daily doses of <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">brivaracetam</a> ranging from 20 to 200 mg/day [<a href="#rid6">6-9</a>]. In the largest individual trial (n = 768), the proportion of patients with a ≥50 percent reduction in seizure frequency was 39 percent for patients randomly assigned to brivaracetam 100 mg/day, 38 percent for brivaracetam 200 mg/day, and 22 percent for placebo [<a href="#rid6">6</a>]. More limited data suggest that brivaracetam has activity in adults with generalized epilepsy [<a href="#rid10">10</a>] but not in children with progressive myoclonic epilepsy [<a href="#rid11">11</a>]. It does not appear to add benefit in combination with <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">Brivaracetam</a> is metabolized primarily (approximately 60 percent) by cytochrome P450 (CYP)-independent hydrolysis and secondarily (approximately 30 percent) via hepatic CYP2C19 to inactive metabolites. The <em>CYP2C19</em> gene is polymorphic, and polymorphisms associated with reduced CYP2C19 function have the potential to diminish brivaracetam metabolism and thereby increase toxicity. (See  <a class="medical medical_review" href="/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'CYP isoenzymes and drug metabolism'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">Brivaracetam</a> does not induce drug-metabolizing enzymes in the liver and weakly inhibits CYP2C19  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Nonetheless, clinicians should be aware of several potential interactions with concomitant antiseizure medications. Brivaracetam may increase the plasma concentrations of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> and the active (10,11-epoxide) metabolite of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> via inhibition of epoxide hydroxylase. Of note, routine carbamazepine serum measurements do not assess for accumulation of active carbamazepine-epoxide metabolite, but this metabolite can be measured as a separate test (see <a class="local">'Carbamazepine'</a> below). The concurrent use of phenytoin, carbamazepine, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, and other CYP2C19 inducers is associated with decreased plasma concentrations of brivaracetam  (<a class="graphic graphic_table graphicRef80801" href="/d/graphic/80801.html" rel="external">table 4A</a>) [<a href="#rid12">12</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The manufacturer's recommended starting dose for adults and children 16 years of age and older is 50 mg twice daily [<a href="#rid13">13</a>]. The dose can be adjusted down to 25 mg twice daily or increased to 100 mg twice daily based upon therapeutic response and tolerability. Lower doses are recommended for patients with hepatic impairment. For children one month to less than 16 years of age, the dose is based upon body weight and is administered twice daily. The drug is available in both oral and intravenous (IV) formulations [<a href="#rid14">14</a>]. When oral administration is temporarily not feasible, <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">brivaracetam</a> may be given by IV administration. The dose and frequency for the IV preparation are the same as for the oral tablets and oral solution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects of <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">brivaracetam</a> are somnolence, dizziness, fatigue, and nausea  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5A</a>). Across multiple randomized trials, psychiatric adverse effects occurred more commonly in patients treated with brivaracetam than placebo (13 versus 8 percent) [<a href="#rid13">13</a>]. In a randomized controlled trial of 760 patients, the most common psychiatric side effects of brivaracetam were irritability (3 versus 0.4 percent), anxiety (2.2 versus 1.1 percent), insomnia (2 versus 1.1 percent), and depression (0.8 versus 0.4 percent) [<a href="#rid6">6</a>]. Severe hypersensitivity reactions have been reported, including bronchospasm and angioedema  (<a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 5B</a>).</p><p></p><p class="bulletIndent1">The comparative tolerability between <a class="drug drug_general" data-topicid="106990" href="/d/drug information/106990.html" rel="external">brivaracetam</a> and <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> is not yet known. A 2021 systematic review identified five studies that included a subset of people with epilepsy who switched from levetiracetam to brivaracetam, which was associated with improvement in behavioral adverse events in 33 to 83 percent of patients [<a href="#rid15">15</a>]. Still, a retrospective postmarketing study included in the systematic review also found that patients with a history of behavioral adverse effects on levetiracetam were at increased risk for behavioral adverse effects from brivaracetam (odds ratio 3.5) [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H2120180331"><span class="h2">Cannabidiol</span><span class="headingEndMark"> — </span>The mechanism of action that underlies the antiseizure properties of cannabidiol is not well understood, but it does not appear to involve its effects on cannabinoid receptors.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="118275" href="/d/drug information/118275.html" rel="external">Cannabidiol (pharmaceutical)</a> is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age and older. The efficacy of cannabidiol for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome is reviewed separately. (See  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis", section on 'Cannabidiol'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="118275" href="/d/drug information/118275.html" rel="external">Cannabidiol (pharmaceutical)</a> is metabolized in the liver by CYP3A4 and CYP2C19 [<a href="#rid17">17</a>]. It is also a substrate of UGT1A7, UGT1A9, UGT2B7, and an inhibitor of CYP2C19 and BSEP/ABCB11, with the potential for multiple drug interactions. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="118275" href="/d/drug information/118275.html" rel="external">Cannabidiol (pharmaceutical)</a> is an oral solution (100 mg/mL) [<a href="#rid18">18</a>]. The initial dose is 2.5 mg/kg twice daily by mouth. For seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, the dose can be increased after one week to the suggested maintenance dose of 5 mg/kg twice daily, and may be increased, if needed for further seizure control, up to a maximum of 10 mg/kg twice daily (total 20 mg/kg per day). For seizures associated with tuberous sclerosis complex, the dose may be increased each week by 2.5 mg/kg twice daily, as tolerated, to a recommended maintenance dose of 12.5 mg/kg twice daily (total 25 mg/kg per day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse reactions with cannabidiol are diarrhea, somnolence, decreased appetite, transaminase elevations, fatigue, malaise, insomnia and other sleep problems, and infections [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Serum transaminase (alanine transaminase [ALT] and aspartate transaminase [AST]) and total bilirubin levels should be obtained at baseline and then at one, three, and six months after starting treatment, and periodically thereafter as clinically indicated, or within one month of change in cannabidiol dosing or with changes in other medications that affect liver function [<a href="#rid18">18</a>]. Cannabidiol should be discontinued or interrupted if symptoms or signs of liver dysfunction develop.</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Carbamazepine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> binds to voltage-dependent sodium channels, probably after they change from the activated to the inactivated state. This binding extends the inactivated phase and inhibits the generation of rapid action potentials when the cell is experiencing incoming depolarizing trains. This effect increases with the rate of neuronal firing.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> has broad use as an antiseizure medication for the treatment of focal and generalized seizures. It is also effective for the treatment of affective illnesses such as bipolar disorder and chronic pain syndromes such as trigeminal neuralgia. In a 2013 systematic review, the International League Against Epilepsy (ILAE) concluded that carbamazepine is established as effective as initial monotherapy for adults with focal seizures, and is possibly effective for children with focal seizures [<a href="#rid19">19</a>]. It is potentially effective as initial monotherapy for adults and children with generalized-onset tonic clonic seizures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">Carbamazepine</a> is approximately 70 percent protein bound. It is metabolized in the liver by CYP3A4 and is a potent and broad-spectrum inducer of the CYP system  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). The main metabolite, carbamazepine 10,11-epoxide, has anticonvulsant activity and can be measured in the serum.</p><p></p><p class="bulletIndent1">A number of drugs can influence the serum concentration of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>  (<a class="graphic graphic_table graphicRef80801" href="/d/graphic/80801.html" rel="external">table 4A</a>). Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>. Carbamazepine may reduce the effectiveness of most forms of hormonal contraception  (<a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The usual initial starting dose of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> is 2 to 3 mg/kg per day orally (eg, 100 to 200 mg daily for most patients) given two, three, or four times daily; the dose is increased every five days to 10 mg/kg daily (eg, 800 to 1200 mg/day). Generally, three-times-daily dosing of the immediate-release formulation is recommended. However, if patients experience side effects two to four hours after a dose, then the total daily dose could be redistributed over four doses or a switch made to an extended-release formulation. Measurement of serum sodium concentration is suggested prior to initiation of therapy and again once the patient reaches a therapeutic dose. (See <a class="local">'Hyponatremia'</a> below.)</p><p></p><p class="bulletIndent1">Extended-release oral formulations allow for twice-daily dosing with more stable blood levels. A systematic review of 10 randomized trials comparing immediate-release with controlled-release <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> found a trend toward improved tolerability for controlled-release carbamazepine but mixed results on seizure control, with most trials showing no significant difference between the two formulations [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Serum <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> levels should be measured initially at three, six, and nine weeks, with a goal level of 4 to 12 mcg/mL (17 to 51 micromol/L). Frequent levels are needed early in therapy due to autoinduction, which results in decreased serum concentrations. Further increases up to 15 to 20 mg/kg per day (up to 2 grams per day or higher in selected patients) may be necessary after two to three months because of CYP autoinduction. Serum levels subsequently should be checked at least every two months until successive determinations are constant, more frequently if carbamazepine doses or concomitant antiseizure medication doses are changed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common systemic side effects of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> include nausea, vomiting, diarrhea, hyponatremia, rash, pruritus, and fluid retention  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>). Patients who develop a rash with carbamazepine are more likely to develop one with <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, or <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, and vice versa [<a href="#rid21">21</a>]. Men taking carbamazepine have higher rates of sexual dysfunction and low testosterone levels, which may be reversible if carbamazepine is withdrawn [<a href="#rid22">22,23</a>]. Decreased thyroid hormone levels of uncertain clinical significance have been reported in patients taking carbamazepine [<a href="#rid24">24,25</a>].</p><p></p><p class="bulletIndent1">Neurotoxic side effects include drowsiness, dizziness, blurred or double vision, lethargy, and headache. Hyponatremia related to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> is discussed separately. (See <a class="local">'Hyponatremia'</a> below.)</p><p></p><p class="bulletIndent1">Potentially life-threatening adverse events related to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and bone marrow suppression:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SJS/TEN</strong> – Most cases of SJS/TEN occur during the first eight weeks of therapy [<a href="#rid26">26,27</a>]. Screening for the HLA-B*1502 allele is recommended prior to starting <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> in patients with Asian ancestry due to the risk of SJS and TEN. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow suppression</strong> – Leukopenia occurs in approximately 12 percent of children and 7 percent of adults with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> treatment [<a href="#rid28">28</a>]. It may be transient or persistent and does not usually require immediate discontinuation of carbamazepine therapy. The onset is typically within the first three months of treatment. Patients who have a low or low-normal white blood cell (WBC) or neutrophil count before carbamazepine treatment may be at higher risk for developing carbamazepine-induced leukopenia or neutropenia.</p><p></p><p class="bulletIndent2">Aplastic anemia (pancytopenia) is a rare, idiosyncratic, non-dose-related side effect that is most likely to occur within the first three or four months after initiating <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> therapy. Daily laboratory checks would be necessary to monitor for aplastic anemia, agranulocytosis, and thrombocytopenia because of their rapid onset [<a href="#rid28">28</a>], and such frequent monitoring is neither practical nor necessary for most patients taking carbamazepine. A more suitable approach is to monitor for aplastic anemia by informing patients and clinicians to carefully watch for signs and symptoms [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2">Some experts recommend monitoring WBC counts of high-risk patients during the first three months of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> treatment, with the monitoring frequency determined by results of each laboratory value. WBC counts less than 3000/microL or neutrophil counts below 1000/microL warrant either a decrease in carbamazepine dose with frequent WBC monitoring or carbamazepine discontinuation [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H1002085322"><span class="h2">Cenobamate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">Cenobamate</a>, a tetrazole alkyl carbamate derivative, is an inhibitor of voltage-dependent sodium channels and may enhance gamma-aminobutyric acid (GABA) inhibition through modulation of the GABA(A) receptor.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">Cenobamate</a> was approved in late 2019 by the US Food and Drug Administration (FDA) for the treatment of focal (partial-onset) seizures in adults [<a href="#rid29">29</a>]. Cenobamate should be reserved for adults with treatment-resistant focal seizures.</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">cenobamate</a> was established in two randomized controlled trials that enrolled over 650 adults with focal seizures [<a href="#rid29">29-31</a>]. In one of these trials, 437 adults who were refractory to treatment with at least one antiseizure medication were assigned in a 1:1:1:1 ratio to once daily treatment with either cenobamate 100 mg, 200 mg, 400 mg, or placebo [<a href="#rid30">30</a>]. After a 6-week titration phase and 12-week maintenance phase, the median percentage reductions in seizure frequency for the cenobamate 100 mg/day, 200 mg/day, and 400 mg/day dose groups were 35.5, 55, and 55 percent respectively, compared with 24 percent for the placebo group. Responder rates (ie, the percentage of patients achieving a ≥50 percent reduction in seizures) for the cenobamate 100 mg/day, 200 mg/day, and 400 mg/day dose groups were 40, 56, and 64 percent, respectively, compared with 25 percent for the placebo group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">Cenobamate</a> is primarily metabolized by glucuronidation via UGT2B7 and to a lesser extent by UGT2B4, and by oxidation via CYP2E1, CYP2A6, CYP2B6, and to a lesser extent by CYP2C19 and CYP3A4/5. Cenobamate may increase the serum concentrations of <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and CYP2C19 substrates, and may decrease the serum concentrations of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, and CYP2B6 and CYP3A substrates. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The recommended initial dose of oral <a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">cenobamate</a> is 12.5 mg once daily for the first two weeks, followed by a slow upward titration: 25 mg once daily for weeks 3 and 4, 50 mg once daily for weeks 5 and 6, 100 mg once daily for weeks 7 and 8, 150 mg once daily for weeks 9 and 10, and 200 mg once daily (the recommended maintenance dose) for week 11 and thereafter [<a href="#rid32">32</a>]. The dose may be further increased by 50 mg once daily every two weeks if necessary based upon response and tolerability, to a maximum dose of 400 mg once daily. When cenobamate is discontinued, the dose should be titrated down gradually over at least two weeks.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">Cenobamate</a> is not recommended for patients with severe hepatic impairment or end-stage renal disease; the maximum dose should not exceed 200 mg/day for patients with mild to moderate hepatic impairment [<a href="#rid32">32</a>]. Lower doses may be needed for patients with mild to moderate renal disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most frequent adverse events in clinical trials of <a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">cenobamate</a> were dose-dependent somnolence, dizziness, headache, fatigue, and diplopia [<a href="#rid30">30,32</a>]. Patients should be monitored for drowsiness, fatigue, and suicidal ideation and behavior. The label recommends advising patients not to drive or operate machinery until they have gained sufficient experience with cenobamate [<a href="#rid32">32</a>]. Other potential adverse effects include QT shortening and rare occurrences of drug reaction with eosinophilia and systemic symptoms (DRESS, also known as multi-organ hypersensitivity). (See  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="bulletIndent1">Familial short QT syndrome and hypersensitivity to <a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">cenobamate</a> are contraindications to its use.</p><p></p><p class="bulletIndent1">There are few data regarding the risk of <a class="drug drug_general" data-topicid="126259" href="/d/drug information/126259.html" rel="external">cenobamate</a> use in pregnancy or lactation, but animal data suggests possibility of fetal harm [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H1953587045"><span class="h2">Clobazam</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">Clobazam</a>, a benzodiazepine, binds to the GABA(A) receptor and facilitates the inhibitory action of endogenous GABA by increasing neuronal membrane permeability to chloride ions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">Clobazam</a> is approved by the FDA for use as an adjunctive therapy in patients two years of age and older with Lennox-Gastaut syndrome (LGS) (see  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>). Clobazam is widely used in other countries outside the United States for the treatment of focal seizures.</p><p></p><p class="bulletIndent1">In a systematic review, the ILAE concluded that <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a> was potentially effective as initial monotherapy for children with focal seizures [<a href="#rid19">19</a>]. However, data are limited to support its use as monotherapy [<a href="#rid33">33</a>]; clobazam is typically used as adjunctive therapy. The evidence for clobazam in LGS is reviewed separately. (See  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">Clobazam</a> is metabolized in the liver by cytochrome P450 (CYP) and non-CYP transformations and is a moderate inhibitor of CYP2D6. Dose adjustments are required in patients with hepatic insufficiency  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – For patients two years of age or older and ≤30 kg body weight, <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a> may be started at 5 mg per day in one dose, typically given at bedtime [<a href="#rid34">34</a>]. The dose may be increased in intervals no shorter than every seven days to a maximum total dose of 20 mg per day; doses &gt;5 mg should be given in divided doses twice daily. For patients &gt;30 kg body weight, clobazam may be started at 10 mg in two divided doses and increased in intervals no shorter than every seven days to a maximum total dose of 40 mg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a> include somnolence and sedation, dysarthria, drooling, aggression or other behavioral changes, infections, and constipation; of these, tiredness and behavioral changes are most common [<a href="#rid35">35</a>]. In clinical trials, the incidence of adverse effects was not significantly different in low-dose, high-dose, or placebo-treated patients [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1">Rare cases of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) have also been reported; such reactions can occur at any time, but the likelihood may be greater during the first eight weeks of <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a> treatment or when the drug is stopped and restarted [<a href="#rid34">34,38-40</a>].</p><p></p><p class="headingAnchor" id="H2809262865"><span class="h2">Clonazepam</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">Clonazepam</a>, a benzodiazepine, binds to the GABA(A) receptor and facilitates the inhibitory action of endogenous GABA by increasing neuronal membrane permeability to chloride ions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">Clonazepam</a> is most often used as an adjunctive therapy for myoclonic and atonic seizures. It is FDA-approved for use in Lennox-Gastaut syndrome (akinetic and myoclonic seizures) and absence seizures unresponsive to succinimides. Clonazepam is seldom used to treat childhood absence epilepsy, but has a role in complex epilepsy syndromes with hard-to-treat absence seizures.</p><p></p><p class="bulletIndent1">In a systematic review, the ILAE concluded that <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> was potentially effective as initial monotherapy for adults and children with focal seizures [<a href="#rid19">19</a>]. However, data are limited to support its use as monotherapy [<a href="#rid33">33,41</a>]; clonazepam is typically used as adjunctive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">Clonazepam</a> is metabolized in the liver, mainly by cytochrome P450 isoenzyme 3A4 (CYP3A4), with potential for interactions involving other CYP3A4 substrates. Drug-drug interactions can be searched using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The starting dose of <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> in adults is 0.5 to 1 mg/day when used as adjunct therapy, or 0.5 to 1.5 mg/day when used as monotherapy, with weekly increments of 0.5 to 1 mg/day as needed and tolerated (maximum 20 mg daily). The usual maintenance dose is 2 to 8 mg daily in one or two divided doses. The dose in infants, children, and adolescents is based upon weight.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> include mainly drowsiness, ataxia, and behavioral changes [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H3054173831"><span class="h2">Eslicarbazepine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">Eslicarbazepine</a> is structurally similar to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>, with which it shares some metabolites. It is thought to act through preferential blockade of voltage-gated sodium channels in rapidly firing neurons, although there may be other mechanisms of action [<a href="#rid43">43</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">Eslicarbazepine</a> is approved as monotherapy and for the adjunctive treatment of focal-onset seizures in adults and children as young as four years of age. In a meta-analysis of seven randomized controlled trials, patients treated with eslicarbazepine once daily were more likely to achieve a greater than 50 percent reduction in seizure frequency compared with those receiving placebo (risk ratio [RR] 1.57, 95% CI 1.34-1.83) [<a href="#rid44">44</a>]. In the largest individual randomized trial (n = 640), a greater than 50 percent reduction in seizures (responder rate) was observed in more patients treated with eslicarbazepine 1200 mg per day than placebo (43 versus 23 percent) [<a href="#rid45">45</a>]. The responder rate was also improved in patients treated with eslicarbazepine 800 mg per day versus placebo (31 versus 23 percent), but the result was not statistically significant. Adverse effects led to treatment discontinuation in 26 percent of those treated at 1200 mg per day, 12 percent of those treated at 800 mg per day, and 8 percent of those treated with placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">Eslicarbazepine</a> is given orally as an acetate prodrug that is converted to its active form in the liver. Eslicarbazepine achieves a maximum concentration in two to three hours after oral ingestion [<a href="#rid46">46</a>]. Concentrations are unaltered by food. The elimination half-life of eslicarbazepine is 13 to 20 hours.</p><p></p><p class="bulletIndent1">It is a weak inducer of CYP3A4 and uridine diphosphate-glucuronosyltransferase (UGT) 1A1 and a moderate inhibitor of CYP2C19  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">Eslicarbazepine</a> undergoes extensive metabolism via glucuronidation, and coadministration with UGT inducers such as <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> has been associated with decreased eslicarbazepine drug levels. Conversely, phenytoin levels may increase with coadministration of eslicarbazepine, and adjustment of phenytoin dose may be needed  (<a class="graphic graphic_table graphicRef55399" href="/d/graphic/55399.html" rel="external">table 4B</a>). Eslicarbazepine is not subject to autoinduction.</p><p></p><p class="bulletIndent1">According to manufacturer pharmacokinetic data, <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">eslicarbazepine</a> can, in a dose-related manner, decrease concentrations of coadministered CYP3A4 substrates (eg, <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a>) and levonorgestrel- and ethinyl estradiol-containing hormonal contraceptives [<a href="#rid47">47</a>]. Women of childbearing potential should use additional or alternative nonhormonal contraception [<a href="#rid47">47,48</a>]. Eslicarbazepine may alter <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> concentrations [<a href="#rid49">49</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">Eslicarbazepine</a> and <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> share the same main active metabolite (S-licarbazepine or S-10-monohydroxy metabolite [MHD]), and combined use should be avoided due to the increased risk for adverse or toxic effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The recommended starting dose in adults is 400 mg once daily, which can be increased after one to two weeks to a recommended maintenance dose of 800 mg daily. Depending upon response, daily dose may be further increased to a maximum of 1200 mg. Dose adjustment is needed for renal impairment. Its use is not recommended in patients with severe liver impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects of <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">eslicarbazepine</a> are dizziness, drowsiness, nausea, headache, diplopia, fatigue, vertigo, ataxia, blurred vision, and tremor  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5A</a>). In clinical trials, these side effects occurred more frequently during initial use and when given at the maximum dose of 1200 mg daily [<a href="#rid45">45</a>]. Eslicarbazepine has been associated with an increase in the PR interval, abnormal liver function tests (LFTs), and hyponatremia. Concomitant treatment with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> increases the incidence of diplopia, abnormal coordination, and dizziness  (<a class="graphic graphic_table graphicRef80801" href="/d/graphic/80801.html" rel="external">table 4A</a>). Measurement of serum sodium concentration is suggested prior to initiation of therapy and again once the patient reaches a therapeutic dose. (See <a class="local">'Hyponatremia'</a> below.)</p><p></p><p class="bulletIndent1">Rare but serious adverse effects include SJS/TEN. In clinical trials, 1 to 3 percent of patients who received <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">eslicarbazepine</a> developed rash [<a href="#rid47">47</a>]. Eslicarbazepine should not be used in patients with a history of hypersensitivity due to <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, as these drugs are structurally related. Its use should be discontinued if dermatologic reaction or other signs of hypersensitivity develop. Risk factors for hypersensitivity have not been established, and it is not yet known whether certain HLA alleles increase the risk of serious dermatologic reactions, as is the case with carbamazepine. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'HLA polymorphism and pharmacogenetics'</a>.)</p><p></p><p class="headingAnchor" id="H1739745898"><span class="h2">Ethosuximide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">Ethosuximide</a> diminishes T-type calcium currents in thalamic neurons, which are further reduced as membrane potentials become more hyperpolarized [<a href="#rid50">50</a>]. The metabolite of trimethadione, another antiseizure medication for absence seizures, acts similarly.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">Ethosuximide</a> is effective for the treatment of absence seizures; it has no activity against generalized tonic-clonic or focal seizures. A randomized clinical trial compared ethosuximide, valproate, and <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> in 453 children with childhood absence epilepsy [<a href="#rid51">51</a>]. Ethosuximide and <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a> were found to be more effective than lamotrigine in eliminating seizures; ethosuximide had a more favorable adverse-event profile compared with valproic acid. (See  <a class="medical medical_review" href="/d/html/14450.html" rel="external">"Childhood absence epilepsy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">Ethosuximide</a> is metabolized in the liver via CYP3A. There are no significant reactions reported with other drugs. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The recommended dose of <a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">ethosuximide</a> is 20 to 40 mg/kg per day in one to three divided doses. Blood levels should be checked initially after one to three weeks, with a goal therapeutic concentration of 40 to 100 mcg/mL (280 to 700 micromol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The major side effects include nausea, vomiting, sleep disturbance, drowsiness, and hyperactivity  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>).</p><p></p><p class="headingAnchor" id="H3008004167"><span class="h2">Felbamate</span><span class="headingEndMark"> — </span>The mechanism of action of <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a> is not well understood. It blocks the channel at the N-methyl-D-aspartate (NMDA) excitatory amino acid receptor and augments gamma-aminobutyric acid (GABA) function in rat hippocampal neuronal cultures [<a href="#rid52">52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">Felbamate</a> can be used to treat focal seizures and is mainly used to treat the Lennox-Gastaut syndrome (LGS), a mixed seizure disorder of childhood onset associated with multiple seizure types, slow spike-wave pattern on the interictal electroencephalogram (EEG), intellectual disability, and resistance to standard antiseizure medications. (See  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>.)</p><p></p><p class="bulletIndent1">However, <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a> is <strong>not</strong> recommended for first-line therapy of seizures because of the potential for serious adverse reactions [<a href="#rid53">53</a>]. The manufacturer recommends that written consent be obtained prior to beginning therapy.</p><p></p><p class="bulletIndent1">In a placebo-controlled randomized trial of 73 patients with LGS, adjunctive treatment with <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a> was effective for reducing the frequency of seizures [<a href="#rid54">54</a>], and the improvement was sustained in an open-label follow-up study [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">Felbamate</a> is metabolized in the liver by the cytochrome P450 (CYP) system (primarily CYP3A4) and approximately 50 percent is excreted renally as unchanged drug  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Felbamate can increase toxicity of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and the active epoxide metabolite of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid56">56-58</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The initial dose of <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a> for adults and adolescents age 14 years or more is 1200 mg/day in three to four divided doses, increasing by 600 mg to 1200 mg per week, based upon response and tolerance, to a maximum total daily dose of 3600 mg [<a href="#rid33">33</a>]. For children ages 2 to 14 years, the initial dose is 15 mg/kg per day given in three to four divided doses, increasing by 15 mg/kg per day at weekly intervals based upon response and tolerance, with a maximum total daily dose of 45 mg/kg per day or 3600 mg per day, whichever is less.</p><p></p><p class="bulletIndent1">Therapeutic blood levels of <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a> have not been established, but patients should have baseline laboratory testing including a complete blood count and liver enzymes. These tests should continue to be monitored every one to two months, and monitoring of the blood counts should continue following cessation of therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most frequent adverse effects associated with <a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">felbamate</a> are anorexia, nausea, and vomiting [<a href="#rid33">33</a>]. Others include insomnia, irritability, headache, and weight loss.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8934" href="/d/drug information/8934.html" rel="external">Felbamate</a> has been associated with fatal aplastic anemia and hepatic failure  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>). These severe toxicities have been reported in a higher proportion of patients treated with felbamate compared with those treated with other antiseizure medications. Aplastic anemia may not occur for several months after the start of therapy, may not be reliably detected by routine testing, and may continue to be a risk for patients even after cessation of the drug. (See  <a class="medical medical_review" href="/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2328615630"><span class="h2">Gabapentin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> binds to the auxiliary alpha-2-delta subunit of a voltage-dependent calcium channel, which may inhibit inward calcium currents and attenuate neurotransmitter release [<a href="#rid59">59</a>]. Structure/activity studies of gabapentin and related compounds show a strong correlation between binding at this receptor and anticonvulsant activity, further supporting that this is the site of action relevant in epilepsy [<a href="#rid60">60,61</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> is used as add-on therapy for refractory focal seizures [<a href="#rid62">62,63</a>]. The American Academy of Neurology (AAN) guidelines state that gabapentin is considered possibly effective for initial monotherapy in patients age 60 years and older with newly diagnosed focal epilepsy [<a href="#rid64">64</a>], although it is not approved by the FDA for this indication [<a href="#rid65">65</a>]. There is moderate-quality evidence that gabapentin is effective as adjunctive treatment for patients with drug-resistant focal epilepsy [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> is absorbed by means of saturable amino acid transport systems in the gut. Though less convenient, more frequent dosing will result in increased bioavailability when daily doses &gt;3600 mg are required [<a href="#rid66">66</a>]. The drug does not bind to plasma protein and is not metabolized; it is excreted entirely in the urine, corresponding with the creatinine clearance; dose adjustments are required in patients with impaired renal function  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Initial dosing suggested by the manufacturer (eg, 300 mg three times daily or 300 mg the first day, 300 mg twice daily the second day, 300 mg three times a day on the third day) may not be well tolerated in some patients, especially older adults, and a lower initial dose and slower titration are often prudent. The dose can be gradually increased as needed to 1800 mg/day in three divided doses. The antiseizure effects of <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> are dose related, and the therapeutic effects of doses less than 900 mg/day may be small. Doses of up to 2400 mg/day have been tolerated in long-term studies in patients with epilepsy [<a href="#rid63">63,67</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> should be taken at least two hours after the use of antacids since concurrent administration decreases its bioavailability.</p><p></p><p class="bulletIndent1">There are no established therapeutic serum levels. Toxic side effects are more common in patients with renal insufficiency, especially in older patients and those with comorbidity. One study found that patients with chronic kidney disease commonly receive inappropriately high doses of <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> for their kidney function [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The major adverse effect of <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> is sedation  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>), and it should be used with caution in combination with other medications that cause sedation, including opioids and benzodiazepines. Additional common side effects include dizziness, ataxia, and weight gain. Misuse and diversion of gabapentin are increasingly recognized; risk factors include a history of substance abuse, especially opioids, and psychiatric comorbidities [<a href="#rid69">69,70</a>]. Respiratory depression, potentially fatal, can occur when gabapentinoids are used with other central nervous system (CNS) depressants such as opioids, or when used to treat elderly patients or patients with respiratory risk factors such as chronic obstructive pulmonary disease (COPD) [<a href="#rid71">71-74</a>]. (See  <a class="medical medical_review" href="/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> may be transported across the placenta and accumulate in breast milk, but the clinical significance of this finding is not clear. (See  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Breastfeeding'</a>.)</p><p></p><p class="headingAnchor" id="H3294997352"><span class="h2">Lacosamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">Lacosamide</a> selectively enhances slow inactivation of voltage-dependent sodium channels; this results in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing [<a href="#rid75">75,76</a>]. Lacosamide also binds to the collapsin response mediator protein 2 (CRMP2), which may be involved in epileptogenesis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – Oral <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a> is FDA-approved for use as monotherapy or adjunctive therapy for focal-onset seizures in patients one month of age and older, and for adjunctive treatment of primary generalized tonic-clonic seizures in patients four years of age and older [<a href="#rid77">77</a>]. In randomized trials, a 50 percent or greater reduction in seizure frequency for placebo, lacosamide 200 mg per day, and lacosamide 400 mg per day occurred in 23, 34, and 40 percent respectively [<a href="#rid75">75,78-81</a>]. The efficacy of lacosamide 600 mg per day was similar to 400 mg per day but was less well tolerated. Secondary efficacy analysis suggested that the 600-mg-per-day dose of lacosamide may provide additional benefits in certain subgroups of patients, specifically those with secondary generalized seizures [<a href="#rid79">79</a>]. An open-label extension of one clinical trial demonstrated that lacosamide was safe and generally well tolerated, with maintenance of efficacy among responders up to five years after treatment initiation [<a href="#rid82">82</a>]. Other reports document similar efficacy for focal-onset seizures in younger patients, ages 1 to 21 years [<a href="#rid83">83-86</a>], and after conversion to monotherapy in adults [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">Lacosamide</a> is completely absorbed after oral administration with 100 percent bioavailability and is eliminated by renal excretion and biotransformation. Lacosamide is not a significant hepatic-enzyme inducer, but strong CYP inhibitors (eg, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) may decrease elimination in the presence of hepatic or renal impairment  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">Lacosamide</a> is available as an oral tablet, oral solution, and IV injection. It is FDA-approved for the treatment of partial-onset seizures in patients one month of age and older and as adjunctive therapy for primary generalized tonic-clonic seizures in patients four years of age and older [<a href="#rid77">77</a>]. Lacosamide is also available as extended-release capsules, which are FDA-approved for the treatment of partial-onset seizures in adults and children weighing at least 50 kg [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">Lacosamide</a> (regular release) should be initiated at a dose of 50 mg twice daily (total 100 mg per day) as adjunctive therapy in adults; the recommended starting dose as monotherapy is 100 mg twice per day (total 200 mg per day) [<a href="#rid77">77</a>]. The dose may be increased at weekly intervals by 100 mg per day to a maintenance dose of 200 to 400 mg (total) per day for adjunctive therapy, and 300 to 400 mg (total) per day for monotherapy. Children should be dosed according to body weight.</p><p></p><p class="bulletIndent1">To achieve maintenance dosage more quickly when clinically indicated, an alternative dosing strategy for adults and children weighing at least 50 kg is to start <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a> with a 200 mg loading dose, followed 12 hours later by starting 100 mg twice daily (total 200 mg per day). The dose may be increased at weekly intervals by 100 mg per day to a maintenance dose of 200 to 400 mg (total) per day for adjunctive therapy, and 300 to 400 mg (total) per day for monotherapy. Children weighing less than 50 kg are dosed according to body weight.</p><p></p><p class="bulletIndent1">In adults, extended-release <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a> for partial-onset seizures is started at 100 mg once daily as adjunctive therapy, and at 200 mg once daily as monotherapy [<a href="#rid88">88</a>]. The maximum recommended dose for both adjunctive therapy and monotherapy is 400 mg once daily. For children weighing at least 50 kg, the initial dose is 100 mg once daily.</p><p></p><p class="bulletIndent1">Dose adjustment should be made in patients with hepatic or renal impairment and should be supplemented after hemodialysis [<a href="#rid77">77,88</a>].</p><p></p><p class="bulletIndent1">The clinical utility of <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a> drug level monitoring has not been established. However, levels could be helpful to guide therapy in children and adolescents [<a href="#rid89">89,90</a>], in patients on concomitant enzyme inducing antiseizure medications [<a href="#rid90">90</a>], and in circumstances for which antiseizure levels are generally useful (eg, if nonadherence is suspected, concurrent medications are changed, or as a baseline when a therapeutic dose is established for an individual patient).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">Lacosamide</a> tends to be well tolerated. Dizziness, nausea, vertigo, abnormal coordination, and ataxia are the most frequently reported side effects [<a href="#rid75">75,80,82,91</a>]. One case series described an increase in these symptoms when lacosamide was co-prescribed with other antiseizure medications that block voltage-dependent sodium channels [<a href="#rid92">92</a>]. Another case series describes exacerbation of seizures with lacosamide in three patients with Lennox-Gastaut syndrome (LGS) [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1">Dose-dependent PR interval prolongations on electrocardiogram (ECG) in some studied patients suggest caution in prescribing <a class="drug drug_general" data-topicid="10268" href="/d/drug information/10268.html" rel="external">lacosamide</a> to those with known conduction problems (eg, atrioventricular block, sinus node dysfunction without a pacemaker, Brugada syndrome), severe ischemic or structural heart disease, or concomitant use of medications that prolong the PR interval. In such patients, a baseline ECG is recommended prior to starting lacosamide and after the maintenance dose has been achieved. Symptomatic second-degree atrioventricular block occurred in a patient after lacosamide was added to an antiseizure medication regimen that included <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, which is also associated with prolongation of the PR interval [<a href="#rid94">94</a>]. One case report describes atrial flutter/fibrillation in a patient on high-dose lacosamide, which resolved with drug discontinuation [<a href="#rid95">95</a>]. Another case report describes second-degree AV heart block and cardiac arrest in a neonate after starting lacosamide [<a href="#rid96">96</a>]. Syncope was reported in 1.2 percent of patients with diabetic neuropathy treated with lacosamide, compared with 0 percent of placebo-treated patients, primarily in patients receiving &gt;400 mg/day; other cases of syncope have occurred in association with cardiac risk factors and concomitant use of drugs that slow atrioventricular conduction [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H2007327377"><span class="h2">Lamotrigine</span><span class="headingEndMark"> — </span>The cellular mechanism of action of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> is not completely understood, and it may have multiple effects. In rodent brain preparations, lamotrigine blocks the repetitive firing of neurons by inactivating voltage-dependent sodium channels. However, there is some evidence that lamotrigine, unlike <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, may selectively influence neurons that synthesize glutamate and aspartate, since it diminishes the release of these excitatory neurotransmitters [<a href="#rid97">97</a>]. These findings suggest that the anticonvulsant effect of lamotrigine may relate to actions on synaptic as well as membrane functions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> is approved by the FDA for the adjunctive treatment of focal-onset seizures in adults and children as young as two years of age, as well as for adjunctive therapy for primary generalized tonic-clonic seizures and LGS [<a href="#rid98">98-100</a>]. Guidelines published by the American Academy of Neurology (AAN) support use of lamotrigine as initial therapy in patients with newly diagnosed focal epilepsy and unclassified generalized tonic-clonic seizures [<a href="#rid64">64</a>]. In randomized controlled trials, lamotrigine as add-on therapy was effective for reducing seizure frequency in adults and children with focal seizures [<a href="#rid64">64,100</a>]. One prospective study in more than 200 patients suggested that it is safe and possibly efficacious for focal seizures in infants aged 1 to 24 months [<a href="#rid101">101,102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> is quickly and totally absorbed when given orally, and plasma concentrations have an apparent linear relationship to dose. The drug is approximately 55 percent bound to plasma proteins, and the liver metabolizes lamotrigine to inactive glucuronide conjugates excreted in the urine  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). In older adults, lamotrigine clearance is reduced by approximately 20 percent compared with younger adults, leading to a concomitant increase in adverse effects in this population [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1">Hormone replacement therapy and hormonal contraceptives increase <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> clearance and are associated with decreased blood levels [<a href="#rid104">104-110</a>]. This can result in increased concentrations during the "placebo" week used with many oral contraceptives, with decreases when the active drug is resumed. This effect appears to be limited to combined estrogen-progestin contraceptives; progestin-only contraceptives have not been found to alter lamotrigine levels [<a href="#rid109">109,110</a>]. Conversely, lamotrigine may reduce the effectiveness of combined estrogen-progestin contraceptives  (<a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 6</a>) [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> clearance also increases by approximately 65 percent in pregnancy and may lead to an increase in seizures [<a href="#rid112">112,113</a>]. Comedication with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> appears to attenuate the increased clearance of lamotrigine that is associated with pregnancy and oral contraceptive use [<a href="#rid114">114</a>]. Frequent monitoring of lamotrigine serum levels and appropriate dose adjustments are advised when hormonal contraception is initiated or withdrawn and during pregnancy and after delivery to avoid clinically significant fluctuations in lamotrigine levels. (See  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Antiseizure medication monitoring and dose adjustment'</a>.)</p><p></p><p class="bulletIndent1">Drug levels are markedly increased by an interaction with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, which inhibits glucuronidation, the main metabolic pathway of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>  (<a class="graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463" href="/d/graphic/80801.html" rel="external">table 4A-C</a>). Levels are decreased in the presence of enzyme-inducing drugs that induce lamotrigine glucuronidation (including <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a>, estrogen-containing oral contraceptives, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, and the protease inhibitors lopinavir/<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> and <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>/ritonavir) [<a href="#rid115">115</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> is excreted in breast milk and may lead to significant serum levels in breastfed infants, although the clinical significance of these findings is uncertain [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Breastfeeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The interactions of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> with other drugs lead to three different dosing schemes [<a href="#rid117">117</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients not taking <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> and not taking drugs that induce glucuronidation (eg, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>), the initial <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> dose is 25 mg every day, increasing to 50 mg per day after two weeks and titrating upward by 50 mg per day every one to two weeks as needed to a usual maintenance dose of 225 to 375 mg per day (in two divided doses) for immediate-release lamotrigine or 300 to 400 mg per day for extended-release lamotrigine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients taking an antiseizure medication or other drug that induces <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> glucuronidation (eg, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>), the initial lamotrigine dose is 25 mg twice daily, increasing to 50 mg twice daily after two weeks and titrating upward by 100-mg-per-day increments every one to two weeks as needed to a usual maintenance dose of 300 to 500 mg per day for immediate-release lamotrigine or 400 to 600 mg per day for extended-release lamotrigine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients taking <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, which inhibits <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> glucuronidation, the initial lamotrigine dose is 12.5 to 25 mg every other day, transitioning to daily dosing with the next scheduled dose change, and increasing by 25 to 50 mg per day every two weeks as needed to a usual maintenance dose of 100 to 200 mg per day for immediate-release lamotrigine or 200 to 250 mg per day for extended-release lamotrigine with valproate alone, and 100 to 400 mg per day (immediate- or extended-release lamotrigine) for patients taking valproate along with drugs that induce glucuronidation (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, certain protease inhibitors).</p><p></p><p class="bulletIndent1">When transitioning from adjunctive <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> therapy to monotherapy, the appropriate lamotrigine dose escalation schedule must be adhered to, if a dose increase of lamotrigine is planned, in order to reduce the risk of serious hypersensitivity (ie, use the escalation schedule that is specific to the presence or absence of a concomitant interacting drug). The maintenance dose of lamotrigine monotherapy is usually 250 to 300 mg/day, although a maintenance dose of up to 400 mg per day (immediate-release) may be warranted in some patients; the concurrent antiseizure medication is gradually withdrawn so as to avoid subtherapeutic serum concentrations, particularly in patients with seizures that are difficult to control.</p><p></p><p class="bulletIndent1">An extended-release formulation of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, which can be given once as opposed to twice daily, provides more stable serum concentrations than the immediate-release formulation, and in one trial was shown to be effective as an adjunctive therapy for focal seizures in individuals greater than 12 years [<a href="#rid118">118</a>]. Substitution of extended-release lamotrigine in the same total daily dose as immediate-release lamotrigine results in maintenance of trough concentrations [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1">Therapeutic serum levels of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> have not been definitively established. However, data from 811 patients who took lamotrigine as monotherapy or adjunctive therapy revealed a significant correlation between lamotrigine serum concentrations and clinical toxicity [<a href="#rid120">120</a>]. Toxicity was defined as any side effect that required a dose decrease or discontinuation of lamotrigine. Toxicity increased with increasing serum lamotrigine levels; 7 percent of patients developed toxicity at &lt;5 mcg/mL compared with 59 percent at &gt;20 mcg/mL; toxicity was uncommon at the most frequently encountered serum concentrations (&lt;10 mcg/mL). To put this in perspective, the highest lamotrigine level encountered in any of the major clinical trials was 8.8 mcg/mL, and most patients in those trials had lamotrigine levels in the low single digits (1.53 to 3.60 mcg/mL) [<a href="#rid120">120</a>]. Thus, the authors of this study suggest an initial target range of 1.5 to 10 mcg/mL for lamotrigine therapy, while noting that efficacy may increase at higher levels for patients with refractory seizures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Systemic side effects of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> include rash and nausea  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>). A benign rash may develop in up to 10 percent of patients during the initial one to two months of therapy and necessitates discontinuation of the drug. Patients who have previously had a rash with another antiseizure medication are more likely to experience rash with lamotrigine [<a href="#rid21">21,27,121</a>]. The risk of developing a life-threatening rash such as SJS, TEN, or angioedema is approximately 1 in 1000 adults; this risk is increased in children. The risk of serious rash may be increased if lamotrigine is started at a dose that exceeds the recommended initial dose, if dose escalation is too rapid, or if lamotrigine is coadministered with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> is contraindicated in patients with hypersensitivity to the drug [<a href="#rid117">117</a>]. Due to its pro-arrhythmic potential, lamotrigine should be avoided in patients who have cardiac conduction disorders (eg, second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (eg, myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies). The concomitant use of other sodium channel blockers may increase the risk of proarrhythmia.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a> is <strong>rarely</strong> associated with acute multiorgan failure, hypersensitivity reactions including drug reaction with eosinophilia and systemic symptoms (DRESS), hemophagocytic lymphohistiocytosis, and disseminated intravascular coagulation [<a href="#rid122">122-124</a>]. (See  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a> and  <a class="medical medical_review" href="/d/html/87499.html" rel="external">"Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p></p><p class="bulletIndent1">Neurotoxic side effects are predominantly dizziness and somnolence. In rare cases, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> has exacerbated or initiated myoclonus and even myoclonic status in juvenile myoclonic and other idiopathic generalized epilepsies and also in Unverricht-Lundborg disease [<a href="#rid125">125,126</a>]. This disappears with withdrawal of the medication and sometimes with lowering the dose. The risk of this side effect is low, and lamotrigine is still considered a treatment option in these patients. Lamotrigine intoxication after deliberate overdose has been associated with status epilepticus in one patient with localization-related epilepsy [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1">Aseptic meningitis was reported in the FDA Adverse Event Reporting System in 40 patients taking <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, according to a 2012 report [<a href="#rid128">128</a>]. Fifteen cases were associated with a recurrence of symptoms on rechallenge, which suggests that the association is likely causal; however, drug-induced meningitis always requires exclusion of an infectious etiology. (See  <a class="medical medical_review" href="/d/html/1296.html" rel="external">"Aseptic meningitis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3177904390"><span class="h2">Levetiracetam</span><span class="headingEndMark"> — </span>The mechanism of action of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> is unknown. However, levetiracetam binds to the synaptic vesicle protein SV2A, which has been linked in animal models to epilepsy [<a href="#rid129">129,130</a>]. Binding at this site may modulate synaptic transmission through alteration of vesicle fusion [<a href="#rid131">131</a>]. There is also evidence that levetiracetam indirectly modulates gamma-aminobutyric acid (GABA) [<a href="#rid132">132,133</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">Levetiracetam</a> is a broad-spectrum antiseizure medication that is widely used as first-line monotherapy for focal and generalized tonic-clonic seizures [<a href="#rid134">134</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">Levetiracetam</a> is approved by the FDA as adjunctive therapy to treat focal-onset seizures in patients one month of age and older with epilepsy, as adjunctive therapy in treating myoclonic seizures in patients aged 12 years or older with juvenile myoclonic epilepsy, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients six years of age and older with idiopathic generalized epilepsy [<a href="#rid135">135-141</a>]. It is also approved as initial monotherapy in Europe for patients 16 years of age and older with newly diagnosed epilepsy to treat partial-onset seizures with or without secondary generalization [<a href="#rid142">142</a>].</p><p></p><p class="bulletIndent1">Evidence from observational studies and randomized trials supports the efficacy of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> as monotherapy for patients with focal seizures [<a href="#rid19">19,143-146</a>] and suggests that it may be effective as monotherapy for generalized seizures [<a href="#rid147">147-149</a>].</p><p></p><p class="bulletIndent1">In a postmarketing surveillance study of 373 patients at a single epilepsy center, both the efficacy of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> and the cumulative probability of remaining on levetiracetam at 12 months (74 percent) compared favorably with published data for <a class="drug drug_general" data-topicid="10115" href="/d/drug information/10115.html" rel="external">vigabatrin</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, and <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> [<a href="#rid150">150</a>]. This was corroborated in a larger, multicenter study in which a 58 percent three-year retention rate was estimated [<a href="#rid151">151</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – Metabolism of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> is independent of the CYP system, limiting the potential for pharmacokinetic interaction with other antiseizure medications, hormonal contraception, or immunosuppressant drugs commonly used in organ transplantation [<a href="#rid152">152,153</a>]. Some studies have found that coadministration of enzyme-inducing antiseizure medications is associated with an approximate 25 percent increase in levetiracetam clearance; however, this is felt to have limited clinical significance [<a href="#rid154">154</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Treatment with <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> is initiated at 500 mg twice daily. levetiracetam appears to have a very rapid onset of action as demonstrated by a significant increase in the proportion of patients who achieved seizure-free status on the first day of levetiracetam 500 mg twice-daily treatment compared with placebo [<a href="#rid155">155</a>]. Levetiracetam may be titrated by 1000 mg every two weeks as needed for seizure control, to a maximum dose of 4000 mg daily. However, doses higher than 3000 mg daily are not established to have additional benefit and may be more likely to cause somnolence [<a href="#rid156">156</a>]. Doses up to 4000 mg daily have been found to be beneficial in observational studies [<a href="#rid139">139</a>], but there is no evidence from randomized controlled trials that 4000 mg daily is more effective than 3000 mg daily in a population of patients with epilepsy [<a href="#rid62">62,64</a>]. Nonetheless, it is possible that individual patients may have better seizure control at 4000 mg than 3000 mg.</p><p></p><p class="bulletIndent1">In one report, an oral load of 1500 mg in a single dose was well tolerated and rapidly yielded therapeutic serum concentrations in 37 adult patients with epilepsy [<a href="#rid157">157</a>]. Weight-based dosing is recommended for children under 16 years: 10 mg/kg twice daily producing levels approximating those of the 500 mg twice daily dose in adults, with 20 mg/kg twice daily a usual target dose for therapeutic concentrations [<a href="#rid158">158</a>].</p><p></p><p class="bulletIndent1">An IV formulation of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> is approved for use in clinical situations when patients are temporarily unable to take oral medication [<a href="#rid159">159-161</a>]. IV infusion of levetiracetam is bioequivalent to oral tablets.</p><p></p><p class="bulletIndent1">An extended-release formulation of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> is available; studies suggest that it is comparably effective and well tolerated as a once-daily medication [<a href="#rid162">162-164</a>].</p><p></p><p class="bulletIndent1">Routine monitoring of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> levels is not required. However, serum levels may be useful in certain conditions expected to influence levetiracetam levels, such as pregnancy, renal insufficiency, and concomitant use of enzyme-inducing drugs (eg, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>). In addition, serum levels can be useful to assess adherence to treatment and to document the level at which seizure control is achieved or the level at which significant adverse events occur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">Levetiracetam</a> is relatively well tolerated. The most common adverse events include fatigue, somnolence, dizziness, and infection (upper respiratory) [<a href="#rid139">139</a>]. Most adverse events associated with levetiracetam are mild to moderate in intensity and most often occur during the initial titration phase  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>).</p><p></p><p class="bulletIndent1">Neuropsychiatric side effects can emerge beyond the initial titration period and may be the most common reason for drug discontinuation. In a postmarketing survey of 354 patient, sedation was the most common side effect of <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a>, occurring in 11 percent, but mood disturbance was not rare (5 percent), and was more likely to lead to discontinuation [<a href="#rid150">150</a>]. Psychiatric adverse effects (behavioral disturbance or psychosis) led to discontinuation in an additional 3 percent. In children, behavioral problems and somnolence are the most commonly reported side effects (11 and 8 percent, respectively) [<a href="#rid165">165</a>]. Some reports suggest that <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">pyridoxine</a> supplementation may reduce the neuropsychiatric adverse effects of levetiracetam, but the studies are mainly retrospective and low quality, failing to control for potential biases [<a href="#rid166">166</a>].</p><p></p><p class="bulletIndent1">Other anecdotal reports and observational studies describe increased agitation and aggression with <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a> that may be problematic in some patients, particularly those who are intellectually disabled and have baseline behavioral problems [<a href="#rid167">167-170</a>]. This patient population may also be at increased risk of a paradoxic worsening of seizures in the first few weeks of starting levetiracetam, particularly when high doses are used [<a href="#rid171">171</a>]. Some have reported that problematic weight loss occurs in a small proportion of patients taking levetiracetam [<a href="#rid172">172-174</a>]. A reversible thrombocytopenia has been linked to levetiracetam in a small number of patients [<a href="#rid175">175-177</a>]. Rare cases of drug reaction with eosinophilia and systemic symptoms (DRESS) related to levetiracetam have also been reported [<a href="#rid40">40</a>]. </p><p></p><p class="headingAnchor" id="H2500078766"><span class="h2">Oxcarbazepine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">Oxcarbazepine</a> is a compound with a similar chemical structure to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and likely a similar mechanism of action. Oxcarbazepine and its active metabolite, 10-monohydroxy metabolite (MHD), block voltage-sensitive sodium channels, increase potassium conductance, and modulate the activity of high-voltage activated calcium channels.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">Oxcarbazepine</a> is indicated as monotherapy in the treatment of focal seizures in patients 4 years of age and older, and as adjunctive therapy for focal seizures in patients 2 years of age and older [<a href="#rid178">178</a>]. The efficacy of oxcarbazepine is comparable to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and other first-line therapies for focal and secondarily generalized tonic-clonic seizures [<a href="#rid179">179,180</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">Oxcarbazepine</a> is almost completely absorbed regardless of food intake. Serum concentrations of its active metabolite, MHD, reach a peak in 4 to 6 hours, with a half-life of 8 to 10 hours. The half-life does not change significantly with chronic administration due to a lack of autoinduction. The concentration of this metabolite decreases during pregnancy and increases after delivery, suggesting the need for close clinical monitoring of women taking the drug during pregnancy. (See  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Antiseizure medication monitoring and dose adjustment'</a>.)</p><p></p><p class="bulletIndent1">Metabolism of <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> occurs in the liver, but only minimally affects the CYP system  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). This represents a major advantage over <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, particularly in patients who require polytherapy. Oxcarbazepine does have the potential to reduce the effectiveness of most forms of hormonal contraception, however, and alternative methods of contraception should be reviewed  (<a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">Oxcarbazepine</a> should not be used in combination with <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">eslicarbazepine</a>, which is an active metabolite of oxcarbazepine. (See <a class="local">'Eslicarbazepine'</a> above.)</p><p></p><p class="bulletIndent1">Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Monotherapy in adults begins with 300 to 600 mg/day, increasing to a dose of 900 to 2400 mg/day in two or three divided doses. An extended-release formulation is also available. In infants and young children, one study showed that higher maintenance doses (60 mg/kg per day) were significantly more effective than lower doses (10 mg/kg per day) when used as adjunctive therapy for focal seizures [<a href="#rid181">181</a>].</p><p></p><p class="bulletIndent1">Measurement of serum sodium concentration is recommended prior to initiation of <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> therapy and again once the patient reaches a therapeutic dose. (See <a class="local">'Hyponatremia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects of <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> are sedation, headache, dizziness, rash, vertigo, ataxia, nausea, hyponatremia (see <a class="local">'Hyponatremia'</a> below), and diplopia  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>). With the exception of hyponatremia, these side effects appear to occur in a frequency similar to patients taking <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid179">179,182</a>]. Studies have also found decreased thyroid hormone levels in patients on both short- and long-term treatment with oxcarbazepine; the clinical significance of these findings is not yet known [<a href="#rid183">183,184</a>]. (See  <a class="medical medical_review" href="/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones", section on 'Drugs that affect thyroid hormone metabolism or clearance'</a>.)</p><p></p><p class="bulletIndent1">Rare but serious hypersensitivity reactions, including SJS, TEN, and multiorgan hypersensitivity, have been associated with <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> use in both children and adults, usually within the first few weeks of starting the drug [<a href="#rid27">27</a>]. As with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, the HLA-B*1502 allele has been associated with increased risk of SJS/TEN in patients with Asian ancestry treated with oxcarbazepine [<a href="#rid185">185-187</a>]. However, the incidence and severity of SJS/TEN related to oxcarbazepine appear to be lower compared with carbamazepine, and the positive predictive value of HLA-B*1502 for SJS/TEN was less than 1 percent in one study [<a href="#rid187">187</a>]. Due to the chemical similarity between the two drugs, available clinical information, and preclinical data showing a direct interaction between oxcarbazepine and HLA-B*1502 protein, the FDA revised the oxcarbazepine label in 2014 to suggest testing for the HLA-B*1502 allele in genetically at-risk populations (ie, those with Asian ancestry) before initiating treatment with oxcarbazepine [<a href="#rid178">178</a>]. Oxcarbazepine, carbamazepine, and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> should be avoided in patients carrying the HLA-B*1502 allele unless the estimated benefits clearly outweigh the risks. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'HLA polymorphism and pharmacogenetics'</a>.)</p><p></p><p class="bulletIndent1">Rare cases of anaphylaxis and angioedema have also been reported in patients taking a first or subsequent dose of <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>. If a patient develops a hypersensitivity reaction, the drug should be discontinued permanently. There have been rare reports of pancytopenia, agranulocytosis, and leukopenia associated with oxcarbazepine [<a href="#rid178">178</a>].</p><p></p><p class="headingAnchor" id="H1857069269"><span class="h2">Perampanel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">Perampanel</a> is an orally active, noncompetitive AMPA-type glutamate receptor antagonist. It appears to inhibit AMPA-induced increases in intracellular calcium, reducing neuronal excitability [<a href="#rid188">188</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">Perampanel</a> is approved by the FDA for the treatment of focal-onset seizures with or without secondary generalization in patients with epilepsy four years of age and older, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older [<a href="#rid189">189</a>]. Randomized trials have found that adjunctive therapy with once-daily perampanel (4 to 12 mg per day) resulted in a &gt;50 percent reduction in seizure frequency in 29 to 36 percent of patients with refractory focal epilepsy, compared with 14 to 26 percent in placebo patients [<a href="#rid190">190-193</a>]. Improved efficacy has been observed with higher doses [<a href="#rid194">194</a>]. Perampanel also decreased the frequency of primary generalized seizures compared with placebo in a trial of 162 patients with drug-resistant idiopathic generalized epilepsy [<a href="#rid195">195</a>]. A 2022 review identified eight studies, mainly retrospective, evaluating perampanel as monotherapy for treating epilepsy and concluded that perampanel monotherapy was associated with favorable safety and efficacy, in line with evidence from clinical trials testing perampanel as adjunctive therapy [<a href="#rid196">196</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">Perampanel</a> is extensively metabolized by the liver, primarily via CYP3A4, CYP3A5, glucuronidation, and potentially other pathways. It has a prolonged and variable half-life (mean 105 hours), which may complicate dose titration and safety washout. Dose adjustments are recommended for patients with mild and moderate hepatic impairment, and the drug is not recommended for patients with severe hepatic or renal impairment, including those on hemodialysis.</p><p></p><p class="bulletIndent1">Clearance of <a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">perampanel</a> is increased, and clinical effect decreased, in patients taking concomitant enzyme-inducing antiseizure medications such as <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>  (<a class="graphic graphic_table graphicRef80801" href="/d/graphic/80801.html" rel="external">table 4A</a> and <a class="graphic graphic_table graphicRef55399" href="/d/graphic/55399.html" rel="external">table 4B</a>) [<a href="#rid194">194,197</a>]. Strong inhibitors of CYP3A4 may modestly increase perampanel exposure  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). When dosed at 12 mg daily, perampanel can decrease the efficacy of levonorgestrel-containing hormonal contraception. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The recommended starting dose of <a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">perampanel</a> is 2 mg taken once daily at bedtime, increasing by 2 mg/day no more frequently than once per week, to a maximum dose of 12 mg daily. Given the long half-life of perampanel, it may take up to two weeks to evaluate the full effect (steady state) of a dose adjustment. In patients taking enzyme-inducing antiseizure medications, the recommended starting dose is 4 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects observed in randomized trials include dizziness, somnolence, headache, fatigue, irritability, gait disturbance, falls, nausea, and weight gain  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5A</a>) [<a href="#rid190">190,191,198,199</a>]. Labeling information includes a boxed warning of serious neuropsychiatric effects including alteration of mood and aggression [<a href="#rid189">189</a>]. In a pooled analysis of the safety data from three randomized trials, the risk of psychiatric adverse effects was dose dependent and was increased compared with placebo for overall psychiatric symptoms (22, 17, and 12 percent for <a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">perampanel</a> 12 mg, 8 mg, and placebo) as well as for more narrowly defined symptoms of hostility/aggression (6, 3, and 0.7 percent, respectively) [<a href="#rid200">200</a>]. A majority of patients with psychiatric adverse effects continued on study, some with dose reductions, and the proportion of patients with a psychiatric adverse effect who discontinued therapy completely was relatively low (14 percent).</p><p></p><p class="bulletIndent1">A smaller randomized trial in adolescents found similar results [<a href="#rid201">201</a>], whereas a retrospective review of 24 patients aged 12 to 18 years treated with <a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">perampanel</a> at a tertiary care center reported a much higher rate of discontinuation (63 percent) [<a href="#rid202">202</a>]. Behavioral side effects were the most common reason for discontinuation and were considered severe in six patients (eg, homicidal ideation, self-harm, physical and verbal aggression). One patient developed oculogyric crisis related to perampanel.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="87037" href="/d/drug information/87037.html" rel="external">Perampanel</a> is classified as a Schedule III drug by the United States Drug Enforcement Administration (DEA) due to its potential for abuse [<a href="#rid203">203</a>].</p><p></p><p class="headingAnchor" id="H4255675246"><span class="h2">Phenobarbital</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a> binds to the GABA(A) receptor, improving the effect of GABA by extending the duration of GABA-mediated chloride channel openings. This process permits an increasing flow of chloride ions across the membrane, causing neuronal hyperpolarization (eg, membrane inhibition to depolarization).</p><p><a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a> is among the oldest antiseizure medications still in use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a> is effective for the treatment of generalized and focal seizures [<a href="#rid33">33</a>]. However, its clinical utility is limited by its sedating effects  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">Phenobarbital</a> is metabolized primarily in the liver by the CYP system and 25 percent is excreted renally as unchanged drug. It is a potent and broad-spectrum inducer of CYP and uridine diphosphate-glucuronosyltransferase (UGT)-glucuronidation  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Phenobarbital may reduce the effectiveness of most forms of hormonal contraception  (<a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1">Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The oral dose of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> is 1 to 5 mg/kg per day; it may also be administered intravenously. Serum phenobarbital concentrations should be checked three to four weeks after the initial dose, with a goal therapeutic level of 10 to 40 mcg/mL (43 to 172 micromol/L). A number of drugs can influence the serum concentration of phenobarbital  (<a class="graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463" href="/d/graphic/80801.html" rel="external">table 4A-C</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most frequent adverse effects of <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> are sedation, reduced concentration, and mood changes including depression [<a href="#rid33">33</a>]. Children may exhibit hyperactivity. Chronic use is associate with an increased risk of decreased bone density, Dupuytren contractures, plantar fibromatosis, and frozen shoulder. Teratogenicity with pregnancy is another risk, with a relatively high rate of major malformations in fetuses exposed to phenobarbital. In addition, in-utero exposure is associated with diminished cognitive ability.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Phenytoin and fosphenytoin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> blocks voltage-dependent neuronal sodium channels, similar to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid204">204</a>]. Other effects of phenytoin include diminishing synaptic transmission, limiting fluctuation of neuronal ionic gradients via sodium-potassium ATPase, and affecting second messenger systems by inhibiting calcium-calmodulin protein phosphorylation.</p><p><a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">Fosphenytoin</a> is the water-soluble prodrug of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> was introduced in the 1930s for use in epilepsy and is still widely prescribed for focal and generalized seizures, for status epilepticus, and as a second-line agent for patients with mixed seizures (myoclonic and tonic-clonic).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions </strong>– The first step in the metabolism of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, which takes place in the liver, involves arene oxidase, which has nonlinear kinetics. Phenytoin is metabolized in the liver and is a potent and broad-spectrum inducer of CYP and UGT-glucuronidation  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Phenytoin may reduce the effectiveness of most forms of hormonal contraception  (<a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1">A number of drugs, including many antiseizure medications, can influence the serum concentration of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>  (<a class="graphic graphic_table graphicRef55399" href="/d/graphic/55399.html" rel="external">table 4B</a>). Renal failure impairs the protein binding of phenytoin; the pharmacologically active free concentration may increase relative to the total concentration. CYP2C9 pharmacogenetic polymorphisms affect phenytoin metabolism and drug levels, although CYP2C9 genotyping is not yet widely performed or mandated. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> can be administered orally or intravenously; the prodrug <a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">fosphenytoin</a> has largely replaced phenytoin for IV use, however. The initial oral dose of phenytoin is 15 mg/kg in three divided doses, followed by a maintenance dose of 5 mg/kg daily in one dose or two divided doses, starting 24 hours after the loading dose. Alternatively, fixed (nonweight) dosing can be used, starting with an initial oral phenytoin dose of 1 gram in three divided doses followed by a maintenance dose of 300 to 400 mg daily in two or three divided doses. For obese patients, the upper limit of the initial loading dose is generally 1 gram.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8480" href="/d/drug information/8480.html" rel="external">Fosphenytoin</a> is administered in <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> equivalents (PE).</p><p></p><p class="bulletIndent1">Like all antiseizure medications, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> dosing should be guided primarily by effect (ie, seizure control) and tolerability. Most, but not all, patients who have normal renal function and serum albumin levels can achieve seizure freedom without side effects with a serum phenytoin concentration of 10 to 20 mcg/mL (40 to 79 micromol/L).</p><p></p><p class="bulletIndent1">Maintenance oral and IV <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> doses are roughly equivalent. Initial blood levels should be obtained two to three weeks after the first dose with a goal concentration of 10 to 20 mcg/mL (40 to 79 micromol/L) in patients with normal renal function. In the presence of low serum albumin or other highly protein-bound drugs (such as <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>), free levels should be followed with a goal of 1 to 2 mcg/mL (4 to 8 micromol/L).</p><p></p><p class="bulletIndent1">After an oral or IV loading dose, the initial <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> blood level can be drawn several hours after the conclusion of the loading dose. The results can be used to guide the determination of the maintenance dose or the need for additional loading. Given the long half-life of phenytoin, serum levels should always be checked within five to seven days following any change (increase or decrease) in the daily dose in order to determine the steady-state serum concentration at the new maintenance dose.</p><p></p><p class="bulletIndent1">In individuals known to be poor or intermediate CYP2C9 metabolizers prior to <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> initiation, guidelines published by the Clinical Pharmacogenetics Implementation Consortium (CPIC) suggest reducing the starting maintenance dose of phenytoin by 50 percent to help avoid phenytoin-related toxicities [<a href="#rid205">205</a>]. These dosing recommendations are considered preliminary, however, and have not been validated by prospective studies. Furthermore, CYP2C9 genotyping is generally not needed in routine clinical practice, particularly since there are many alternatives to phenytoin for antiseizure medication treatment. (See  <a class="medical medical_review" href="/d/html/2904.html" rel="external">"Overview of pharmacogenomics"</a>.)</p><p></p><p class="bulletIndent1">Commercially available brand and generic <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> products may differ in phenytoin content and other formulation characteristics that can affect bioavailability [<a href="#rid206">206</a>]. These differences may occasionally result in an increase [<a href="#rid207">207</a>] or decrease [<a href="#rid208">208</a>] in serum phenytoin levels, which in turn might adversely affect seizure control or cause toxicity when patients are switched from one preparation to another. Therefore, more frequent serum levels and heightened clinical vigilance may be warranted when substituting phenytoin formulations in patients with difficult-to-control seizures or those prone to side effects, particularly in light of phenytoin's nonlinear kinetics and relatively narrow therapeutic window.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The major systemic side effects of <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> are gingival hypertrophy, body hair increase, rash, <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> depletion, and decreased bone density  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>). Neurotoxic side effects include confusion, slurred speech, double vision, ataxia, and neuropathy (with long-term use).</p><p></p><p class="bulletIndent1">Patients who develop a rash with <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> are more likely to develop one with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and vice versa [<a href="#rid21">21</a>]. Phenytoin has been associated with SJS and TEN, particularly during the first eight weeks of therapy [<a href="#rid26">26,27</a>]. As with carbamazepine, this reaction appears to be more common in patients with the HLA-B*1502 allele, which occurs almost exclusively in patients from Asia or with Asian ancestry, including those from South Asia [<a href="#rid209">209,210</a>]. However, the magnitude of the risk of phenytoin in these patients is less clear than with carbamazepine. The FDA recommends avoiding substituting phenytoin for carbamazepine in patients who are known to be positive for HLA-B*1502 unless the estimated benefits clearly outweigh the risks. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'HLA polymorphism and pharmacogenetics'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> is associated with altered bone and mineral metabolism and decreased bone density, related in part to induction of the CYP enzyme system and increased vitamin D catabolism. Calcium and vitamin D supplementation as well as bone mineral density testing are suggested in patients on chronic therapy. (See  <a class="medical medical_review" href="/d/html/2063.html" rel="external">"Antiseizure medications and bone disease", section on 'Treatment and prevention'</a>.)</p><p></p><p class="bulletIndent1">Age-related sexual dysfunction and low testosterone levels are more common in men taking <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> than in controls [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H1886522752"><span class="h2">Pregabalin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> is chemically related to <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and, like gabapentin, also has multiple potential mechanisms of action. It binds to the alpha-2-delta subunit of voltage-gated calcium channels and modulates calcium currents [<a href="#rid211">211,212</a>]. Pregabalin also modulates the release of several neurotransmitters including glutamate, noradrenaline, and substance P. The net result is inhibition of neuronal excitability [<a href="#rid213">213</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> is indicated as adjunctive therapy for focal seizures. Pregabalin is effective for the adjunctive treatment of focal seizures as demonstrated in randomized controlled trials [<a href="#rid214">214,215</a>]. An open-label study in 19 children with refractory epilepsy suggested that pregabalin may be effective in this population as well; however, worsening of seizures was noted in two patients with myoclonic epilepsy [<a href="#rid216">216</a>]. In a randomized trial testing pregabalin as monotherapy for newly diagnosed focal seizures, pregabalin was less effective than <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> but similarly tolerated [<a href="#rid217">217</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> is renally excreted virtually unchanged, and it is not hepatically metabolized. Pregabalin does not induce or inhibit the CYP system  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). In addition, it does not bind to plasma proteins. Thus, pregabalin does not have significant interactions with other antiseizure medications and is not expected to have pharmacokinetic interactions with other drugs [<a href="#rid218">218-220</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> exhibits linear pharmacokinetics, and has a time to maximal plasma drug concentration (Tmax) of approximately one hour and a plasma half-life (T1/2) of approximately six hours [<a href="#rid221">221</a>]. Experimental data suggest that the pharmacodynamic half-life (ie, anticonvulsant effect) of pregabalin is longer than the six-hour pharmacokinetic half-life [<a href="#rid222">222</a>]. The Tmax may be delayed to approximately three hours if the drug is taken with food, but total absorption is not affected by food [<a href="#rid219">219</a>]. Steady state is achieved within 24 to 48 hours.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The starting dose of <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> for the treatment of focal seizures is 150 mg daily given with or without food in either two or three divided doses [<a href="#rid223">223,224</a>]. Pregabalin may be increased to a daily dose of 300 mg after one week and to a maximum daily dose of 600 mg after an additional week, based on patient response and tolerability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common side effects with <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> in randomized trials were dizziness, somnolence, and ataxia  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>) [<a href="#rid215">215,225-228</a>]. Other side effects include weight gain, peripheral edema, blurred or double vision, asthenia, tremor, and abnormal thinking (most often impaired concentration). Respiratory depression, potentially fatal, can occur when gabapentinoids are used with other central nervous system (CNS) depressants such as opioids, or when used to treat elderly patients or patients with respiratory risk factors such as chronic obstructive pulmonary disease (COPD) [<a href="#rid71">71-74</a>]. </p><p></p><p><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a> may also cause euphoria and is classified as a schedule V controlled substance. New-onset myoclonus has been reported in patients taking pregabalin for epilepsy [<a href="#rid229">229</a>].</p><p class="headingAnchor" id="H2689318335"><span class="h2">Primidone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">Primidone</a> is converted into two active metabolites, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> and phenylethylmalonamide (PEMA). Phenobarbital binds to the GABA(A) receptor, thereby extending the duration of GABA-mediated chloride channel openings. PEMA may enhance the activity of phenobarbital.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">Primidone</a> is indicated for focal seizures and generalized tonic-clonic seizures [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">Primidone</a> is metabolized in the liver and is a potent inducer of CYP 450 enzymes, with multiple drug interactions. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The starting dose of <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a> for adults and children age 8 years and older is 100 to 125 mg/day at bedtime for the first three days, increasing to 200 to 250 mg/day in two divided doses for days four to six, 300 to 375 mg/day in three divided for days seven to nine, and 750 mg/day in three divided doses beginning on day 10. The usual maintenance dose is 750 to 1,500 mg/day in three to four divided doses, with a maximum total dose of 2 g/day. For patients already receiving other antiseizure medications, primidone is started at 100 to 125 mg at bedtime, gradually increasing to the maintenance dose as the other antiseizure medication is gradually decreased. When conversion to primidone monotherapy is the goal, the conversion should be completed over at least two weeks or longer.</p><p></p><p class="bulletIndent1">For children under 8 years of age, the weight-based maintenance range is 10 to 25 mg/kg per day given in two to three divided doses; the initial dose is lower and titrated upward. One fixed-dose regimen begins with 50 mg at bedtime for the first three days, increasing to 100 mg/day in two divided doses for days four to six, 200 mg/day in two divided for days seven to nine, and 375 to 750 mg/day in three divided doses beginning on day 10.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common adverse effects of <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a> are similar to <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> and include sedation, impaired concentration, and mood changes. Primidone may cause an acute toxic reaction, thought unrelated to phenobarbital, and characterized by potentially severe sedation, dizziness, ataxia, nausea, and vomiting [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H844055138"><span class="h2">Rufinamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9518" href="/d/drug information/9518.html" rel="external">Rufinamide</a> is structurally unrelated to other marketed antiseizure medications. Rufinamide modulates the activity of sodium channels, prolonging the inactive state. This action is particularly effective in depolarized neurons.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9518" href="/d/drug information/9518.html" rel="external">Rufinamide</a> is approved by the FDA as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (LGS). In a randomized study of 138 patients with LGS, rufinamide was associated with a greater reduction in seizure frequency (33 versus 12 percent), drop attacks (43 versus 1 percent), and seizure severity compared with placebo [<a href="#rid230">230</a>]. Observational studies suggest that rufinamide may be effective as adjunctive therapy in children with other refractory epilepsy syndromes as well [<a href="#rid231">231-233</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9518" href="/d/drug information/9518.html" rel="external">Rufinamide</a> may have efficacy in focal epilepsy as well [<a href="#rid234">234,235</a>]. In a randomized trial of 313 adolescents and adults with refractory focal seizures, rufinamide 3200 mg/day was effective as an adjunctive agent, producing a &gt;50 percent seizure reduction in 28 percent of patients, compared with 19 percent of placebo-treated patients [<a href="#rid236">236</a>]. Another randomized study in 357 patients with refractory focal epilepsy found that rufinamide was effective as adjunctive therapy [<a href="#rid237">237</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – Pharmacokinetic studies show slow absorption (four to six hours to peak concentration) after oral ingestion. Co-ingestion with food increases the extent of absorption. Elimination of <a class="drug drug_general" data-topicid="9518" href="/d/drug information/9518.html" rel="external">rufinamide</a> occurs primarily through renal excretion. Rufinamide is not metabolized by CYP mechanisms and has little effect on the pharmacokinetics of other antiseizure medications [<a href="#rid238">238</a>]. However, potent CYP inducers (eg, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>) may increase the clearance of rufinamide. <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> is associated with reduced clearance of rufinamide. Rufinamide may reduce the effectiveness of oral hormonal contraceptives. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – In children, treatment with <a class="drug drug_general" data-topicid="9518" href="/d/drug information/9518.html" rel="external">rufinamide</a> is initiated at a daily dose of 10 mg/kg per day in two divided doses, increased by 10 mg/kg increments every other day to a target dose of 45 mg/kg per day or 3200 mg/day. Adults are treated initially at 400 to 800 mg per day in two divided doses, increased by 400 to 800 mg per day every two days until maximum daily dose of 3200 mg is achieved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="9518" href="/d/drug information/9518.html" rel="external">Rufinamide</a> is well-tolerated [<a href="#rid239">239</a>]. The most common side effects are somnolence and vomiting. Observed shortening of the QT interval on ECG studies of patients taking rufinamide was not associated with clinical events; however, rufinamide should be avoided in patients with short QT syndrome or taking other drugs that shorten the QT interval. The multiorgan hypersensitivity reaction, also known as drug reaction with eosinophilia and systemic symptoms (DRESS) described with other antiseizure medications has been reported in patients taking rufinamide; all cases have occurred within four weeks of start of treatment.</p><p></p><p class="headingAnchor" id="H91058785"><span class="h2">Stiripentol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="93717" href="/d/drug information/93717.html" rel="external">Stiripentol</a> is an allosteric modulator of the gamma-aminobutyric acid A (GABA-A) receptor with direct activating effects [<a href="#rid240">240</a>]. It also inhibits CYP enzymes, thereby increasing blood levels of some antiseizure medications, especially <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a> [<a href="#rid241">241</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="93717" href="/d/drug information/93717.html" rel="external">Stiripentol</a> is approved by the FDA as adjunct therapy for seizures associated with Dravet syndrome in patients six months of age and older and weighing 7 kg or more who are taking <a class="drug drug_general" data-topicid="8719" href="/d/drug information/8719.html" rel="external">clobazam</a> [<a href="#rid242">242</a>]. Small randomized controlled trials demonstrated that stiripentol as add-on therapy improved seizure control in patients with Dravet syndrome [<a href="#rid243">243-245</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – Metabolism of <a class="drug drug_general" data-topicid="93717" href="/d/drug information/93717.html" rel="external">stiripentol</a> is mainly hepatic. Stiripentol is a minor substrate of CYP1A2 and a major substrate of CYP2C19 and CYP3A4. Stiripentol is a moderate inhibitor of both CYP1A2 and CYP2C19. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The starting dose for <a class="drug drug_general" data-topicid="93717" href="/d/drug information/93717.html" rel="external">stiripentol</a> is listed at 50 mg/kg per day, administered in two or three divided doses [<a href="#rid246">246</a>], but some experts start at 25 mg/kg per day. The dose can be increased in increments of 10 mg/kg per day every one to two weeks to a maximum total daily dose of 3000 mg. The typical tolerated dose in children is 75 mg/kg per day [<a href="#rid247">247</a>], although some children may require up to 100 mg/kg per day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse effects of <a class="drug drug_general" data-topicid="93717" href="/d/drug information/93717.html" rel="external">stiripentol</a> are somnolence, decreased appetite, agitation, ataxia, weight loss, hypotonia, nausea, tremor, dysarthria, and insomnia. In a retrospective study of 82 children with DS, stiripentol adverse effects were reported as mild and not requiring treatment discontinuation in the majority [<a href="#rid248">248</a>].</p><p></p><p class="headingAnchor" id="H1411271083"><span class="h2">Tiagabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">Tiagabine</a> is a second-generation antiseizure medication It is a potent enhancer of GABA action via specific inhibition of GABA reuptake into presynaptic neurons and glia in vitro [<a href="#rid249">249</a>]. Thus, it decreases the elimination of GABA from the synaptic space, making endogenously produced GABA more available for postsynaptic inhibitory effects.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">Tiagabine</a> is used as adjunctive treatment for focal seizures for adults and children 12 years of age and older [<a href="#rid250">250,251</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">Tiagabine</a> is metabolized in the liver by CYP and non-CYP transformations but is not a CYP inducer  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Tiagabine has no significant drug interactions. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The initial dose of <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">tiagabine</a> is 4 to 8 mg/day. It can be titrated in adults at weekly increments of 4 to 8 mg/day until there is a clinical response, or up to 56 mg/day in divided doses. There are no established therapeutic serum levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Major side effects of <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">tiagabine</a> include dizziness, lack of energy, somnolence, nausea, nervousness, tremor, difficulty concentrating, and abdominal pain  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>) [<a href="#rid250">250</a>]. In one study, however, cognitive function after one year of tiagabine monotherapy was similar to that in untreated controls and those on <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> monotherapy [<a href="#rid252">252</a>].</p><p></p><p class="bulletIndent1">There is concern that <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">tiagabine</a> has a proconvulsive effect. In postmarketing reports, new-onset seizures and nonconvulsive status epilepticus have been associated with off-label use of tiagabine for patients without epilepsy [<a href="#rid251">251,253</a>]. (See  <a class="medical medical_review" href="/d/html/14103.html" rel="external">"Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">The apparent discrepancy between this risk in seizure and nonseizure patients may be explainable [<a href="#rid254">254</a>]: <a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">tiagabine</a> was developed and is approved for use as an adjunctive treatment for epilepsy. Virtually all patients treated with tiagabine in clinical trials were taking at least one hepatic-enzyme-inducing antiseizure medication, which decreased the concentration of tiagabine; it is likely that patients without epilepsy have increased concentrations of tiagabine. Furthermore, patients taking tiagabine for off-label indications (psychiatric disease and pain) may also be on other medications that potentially lower the seizure threshold.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10144" href="/d/drug information/10144.html" rel="external">Tiagabine</a> has been associated with nonconvulsive status epilepticus in patients being treated for focal epilepsy in a number of case reports, but this was not observed in randomized, controlled clinical trials or in long-term safety studies [<a href="#rid255">255</a>]. In a retrospective review of patients with localization-related epilepsy, 7.8 percent of 90 tiagabine-treated patients developed nonconvulsive status epilepticus compared with 2.7 percent of the 1165 patients not receiving tiagabine [<a href="#rid256">256</a>]. The frequency of generalized convulsive status epilepticus was not increased. (See  <a class="medical medical_review" href="/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features"</a>.)</p><p></p><p class="headingAnchor" id="H1674372004"><span class="h2">Topiramate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> also has multiple mechanisms of action. It blocks voltage-dependent sodium channels, enhances the activity of GABA at a nonbenzodiazepine site on GABA(A) receptors, and antagonizes an AMPA/kainate-glutamate receptor [<a href="#rid257">257</a>]. It also weakly inhibits carbonic anhydrase in the central nervous system.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> is approved as initial monotherapy in patients ≥2 years of age for focal-onset or primary generalized tonic-clonic seizures [<a href="#rid257">257</a>]. Topiramate is also approved as adjunctive therapy for patients ≥2 years of age with focal seizures or seizures associated with the Lennox-Gastaut syndrome [<a href="#rid64">64,257,258</a>]. One randomized trial in 151 children (ages 6 to 15 years) reported efficacy for topiramate as monotherapy for newly diagnosed epilepsy; seizures were focal onset or generalized onset tonic-clonic [<a href="#rid259">259</a>]. A randomized study in infants aged 1 to 24 months found that adjunctive topiramate (5, 15, or 25 mg/kg per day) was not effective in reducing refractory focal-onset seizures [<a href="#rid260">260</a>]. Topiramate is not approved by the FDA for use in children younger than two years of age [<a href="#rid257">257</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> is metabolized to a minor degree in the liver and is mostly eliminated in the urine [<a href="#rid33">33</a>]. Topiramate may increase <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> concentration, but there do not appear to be any clinically significant interactions with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>  (<a class="graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463" href="/d/graphic/80801.html" rel="external">table 4A-C</a>). Serum levels of topiramate may decline by approximately 30 percent during pregnancy. Conversely, topiramate may reduce the effectiveness of most forms of hormonal contraception  (<a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/2224.html" rel="external">"Management of epilepsy during preconception, pregnancy, and the postpartum period", section on 'Antiseizure medication monitoring and dose adjustment'</a> and  <a class="medical medical_review" href="/d/html/2220.html" rel="external">"Overview of the management of epilepsy in adults", section on 'Contraception'</a>.)</p><p></p><p class="bulletIndent1">Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The starting dose of <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> is 50 mg/day for one week, given in two divided doses titrated at weekly increments of 50 mg to an effective dose. Gradual titration is necessary because of cognitive adverse effects [<a href="#rid33">33</a>]. The recommended total daily dose for adjunctive therapy is 200 mg twice daily. A once-daily extended-release formulation is also available. Therapeutic levels have not been established. Topiramate clearance is increased twofold by enzyme-inducing agents (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>), requiring twofold-increased doses in this setting  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse side effects of <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> include cognitive impairment, weight loss, sedation, paresthesia, fatigue, dizziness, depression, and mood problems  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>) [<a href="#rid33">33,257,261</a>]. Metabolic acidosis is common, mainly in children. Kidney stones occur with therapy in &lt;3 percent. Acute myopia and secondary angle-closure glaucoma are rare. The incidence of most side effects decreases with continued dosing; weight loss and paresthesia are the exceptions [<a href="#rid262">262</a>]. Slower titration of the dose following initiation of therapy may improve tolerance [<a href="#rid263">263</a>]. Topiramate has been associated with decreased sweating leading to heat intolerance and hyperthermia, particularly in children; there have also been case reports of decreased sweating in adults [<a href="#rid264">264,265</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">Topiramate</a> exposure in utero has been associated with an increased risk of oral clefts and low birth weight. (See  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Topiramate'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Impaired cognition</strong> and expressive language is a reported side effect in a minority of patients taking <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, but it is a common reason for discontinuing therapy [<a href="#rid262">262,266</a>]. Studies suggest that this may be a more common phenomenon than patient complaints would indicate, and, at least in some studies, appears to be dose related [<a href="#rid267">267-272</a>]. Impaired cognitive measures with topiramate have been recorded in studies of healthy adult volunteers and children compared with their own baseline as well as with nondrug control patients and with patients taking <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid267">267-269,273,274</a>]. Cognitive and behavioral worsening has also been observed in children with intellectual disability [<a href="#rid275">275</a>]. Adults treated for epilepsy and children treated for obesity have similar cognitive side effects from topiramate [<a href="#rid270">270,271</a>]. The observed cognitive deficits are broad in spectrum but appear to be reversible when the drug is discontinued and attenuated with dose reductions [<a href="#rid268">268,271,276</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Weight loss</strong> is a common dose-related side effect [<a href="#rid262">262,277</a>]. In a double-blind placebo-controlled trial of <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> added to existing antiseizure medications in 264 patients, topiramate was associated with a 2.0 kg mean decrease in weight at three months [<a href="#rid262">262</a>]. A smaller, uncontrolled trial found that at one year, weight loss occurred in 86 percent with a mean cumulative weight loss of 5.9 kg [<a href="#rid278">278</a>]. Weight loss is associated with fat loss and correlates with reduced caloric intake. Follow-up studies suggest that weight loss stabilizes after two to three years of taking the medication [<a href="#rid279">279</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic acidosis</strong> may result from renal bicarbonate loss due to the inhibitory effect of <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> on carbonic anhydrase, which can cause both proximal and distal acidification defects [<a href="#rid280">280-282</a>]. The main clinical manifestation of metabolic acidosis is tachypnea; calcium phosphate nephrolithiasis can also occur [<a href="#rid283">283</a>].</p><p></p><p class="bulletIndent2">Measuring serum bicarbonate at baseline and periodically (for example, every two to four months) is recommended. Gradual dose reduction or cessation of <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> (after tapering) is advised if significant metabolic acidosis develops. Alkali treatment may be helpful if topiramate is continued in patients with symptoms or more marked acidosis [<a href="#rid280">280</a>]. (See  <a class="medical medical_review" href="/d/html/2329.html" rel="external">"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Decreased bone mineral density</strong> may occur as a result of metabolic acidosis, which increases bone resorption [<a href="#rid257">257</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute myopia and secondary angle glaucoma</strong>, characterized by the acute onset of decreased visual acuity and/or ocular pain, occurs rarely in children and adults with <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> therapy (23 cases out of approximately 825,000 users in one postmarketing report [<a href="#rid284">284</a>]), typically within one month of initiating treatment [<a href="#rid257">257,285</a>]. Chronic users of topiramate do not appear to be at increased risk of glaucoma. A few case reports have linked topiramate with an apparently irreversible maculopathy [<a href="#rid286">286</a>]. Visual field defects independent of elevated intraocular pressure have also been reported in association with topiramate [<a href="#rid257">257</a>].</p><p></p><p class="headingAnchor" id="H1398705747"><span class="h2">Valproate</span><span class="headingEndMark"> — </span>Valproate (<a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>) has multiple cellular mechanisms of action consistent with its broad clinical effectiveness [<a href="#rid287">287-290</a>]. Valproate seems to suppress high frequency, repetitive neuronal firing by blocking voltage-dependent sodium channels, but at sites different than <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>. Valproate increases brain GABA concentrations at clinically relevant doses, although the basis of this effect is debated. Valproate does not seem to have any direct effects on the GABA(A) receptor, but GABA release may be enhanced by a presynaptic effect of valproate on GABA(B) receptors. Inhibition of nerve terminal GABA transaminase (GABA-T) probably also increases presynaptic GABA levels. Furthermore, valproate may increase GABA synthesis by activating glutamic acid decarboxylase (GAD). Finally, valproate acts against T-type calcium currents, although this action is weaker than that observed with <a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">ethosuximide</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> is a broad-spectrum antiseizure medication that is used alone and in combination for the treatment of generalized and focal seizures. Valproate is considered the most effective antiseizure medication for idiopathic generalized epilepsy with generalized tonic-clonic seizures [<a href="#rid33">33,291</a>]. It is also effective for absence epilepsy but less well tolerated compared with <a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">ethosuximide</a>. (See  <a class="medical medical_review" href="/d/html/14450.html" rel="external">"Childhood absence epilepsy", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> is tightly protein bound. It is metabolized in the liver and is a moderate broad-spectrum inhibitor of the CYP system and uridine diphosphate-glucuronosyltransferase (UGT)-glucuronidation. Dose adjustments are required in patients with hepatic insufficiency  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). In the presence of hypoalbuminemia, unbound valproate concentrations can be elevated despite normal or low total valproate concentrations and may correlate better with toxicity [<a href="#rid292">292</a>]. Valproate is contraindicated in patients with known urea cycle disorders due to an increased risk of severe hyperammonemia [<a href="#rid293">293</a>]. (See  <a class="medical medical_review" href="/d/html/2923.html" rel="external">"Urea cycle disorders: Management"</a>.)</p><p></p><p class="bulletIndent1">A number of drugs affect the serum level of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>  (<a class="graphic graphic_table graphicRef53463" href="/d/graphic/53463.html" rel="external">table 4C</a>). Oral contraceptive agents may increase valproate clearance and their use is associated with decreased valproate blood levels (median decline 23 percent) during active treatment and higher concentrations during the "placebo" week that is used with many oral hormonal contraceptives [<a href="#rid109">109</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The initial dose of oral <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> is 10 to 15 mg/kg per day for focal-onset seizures with impairment of consciousness or awareness (previously called complex-partial seizures) and 15 mg/kg per day for generalized-onset nonmotor seizures (previously called absence seizures), given in three divided doses. The dose may be increased at one-week intervals by 5 to 10 mg/kg per day as needed. A serum level should be checked one to two weeks after the initial dose, but can be checked three to four days after initiation or dose adjustment; therapeutic concentrations are usually in the 50 to 125 mcg/mL (346 to 875 micromol/L) range.</p><p></p><p class="bulletIndent1">In general, trough serum levels are used to monitor therapy and should be drawn just prior to the next dose for oral <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> and for 24-hour extended-release preparations when the latter is dosed once daily; the timing of the serum level is less important when 24-hour extended-release preparations are dosed twice daily because such dosing results in serum levels that are relatively stable throughout the day. Trough levels can be difficult to obtain in some patients because of logistical problems in having blood drawn at the suggested times. In addition, the optimal timing of serum blood levels for patients taking delayed-release preparations of valproate is uncertain because of the variability in gastrointestinal absorption. In such situations, it is best to obtain serum levels at a time interval relative to the last dose that is feasible, and to use that time consistently.</p><p></p><p class="bulletIndent1">If patients consistently experience side effects after a dose and redistributing the total daily intake into more doses is not feasible, then consider switching to an extended-release formulation, which generally allows for less frequent dosing with more stable blood levels.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> can be delivered intravenously. Current prescribing information recommends slow administration of IV valproate over 60 minutes at a rate of ≤20 mg/minute, or more rapid infusion of single doses up to 15 mg/kg over 5 to 10 minutes at 1.5 to 3 mg/kg per minute [<a href="#rid294">294</a>]. In emergency situations such as status epilepticus, accumulating evidence suggests that a loading dose of valproate of up to 30 mg/kg can be infused safely at rate 10 mg/kg per minute without adverse effects on blood pressure or heart rate [<a href="#rid295">295-300</a>]. Rapid IV loading may be desirable as a way to achieve serum concentrations &gt;100 mcg/mL (&gt;693 micromol/L) quickly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> include nausea, vomiting, hair loss, easy bruising, and tremor  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>). Valproate is also associated with weight gain, obesity, insulin resistance, and the metabolic syndrome [<a href="#rid301">301-304</a>]. Nocturnal enuresis, likely related to impaired sleep efficiency, has been reported in children [<a href="#rid305">305</a>]. Approximately 5 to 10 percent of patients develop alanine aminotransferase (ALT) elevations during long-term valproate therapy; these abnormalities are usually asymptomatic and can even resolve with continuation of the drug. In addition, there are more serious forms of toxicity that can occur with valproate, including hyperammonemic encephalopathy, acute hepatocellular injury, and acute pancreatitis, as discussed below.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> can cause thrombocytopenia and other coagulation disturbances [<a href="#rid306">306-308</a>] and has also been associated with subclinical hypothyroidism with mild to moderate elevations in thyrotropin (TSH) levels [<a href="#rid24">24,183,309,310</a>]. Valproate has also been linked to the polycystic ovarian syndrome [<a href="#rid311">311,312</a>]. A number of case reports have linked valproate to Fanconi syndrome in children with severe disabilities [<a href="#rid313">313</a>]. (See  <a class="medical medical_review" href="/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones", section on 'Drugs that affect thyroid hormone metabolism or clearance'</a> and  <a class="medical medical_review" href="/d/html/7430.html" rel="external">"Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> monotherapy is associated with the highest rate of teratogenicity of all marketed antiseizure medications. Valproate exposure in utero is associated with major malformations and other adverse effects, including neurodevelopmental abnormalities. Valproate should be avoided in pregnancy when possible. (See  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Valproate'</a>.)</p><p></p><p class="bulletIndent1">A number of case reports and case series have described a syndrome of reversible parkinsonism and cognitive decline associated with <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> use [<a href="#rid314">314-318</a>]. The reported frequency of this adverse effect ranges from 1.4 to 5 percent among patients with epilepsy who are treated with valproate. Advanced age and prolonged duration of therapy may be risk factors. The parkinsonism does not respond to levodopa therapy, but usually reverses within a few weeks to months after valproate is discontinued.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Valproate-related hyperammonemic encephalopathy</strong> (VHE) causes acute or subacute encephalopathy, increased seizures, and rarely coma and death [<a href="#rid319">319</a>]. VHE can occur without abnormalities of liver function tests (LFTs) or elevated serum <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> levels. The syndrome resolves within a few days of stopping valproate but may reverse more rapidly with <a class="drug drug_general" data-topicid="10109" href="/d/drug information/10109.html" rel="external">carnitine supplementation</a> or renal hemodialysis. Mild to moderate hyperammonemia, often asymptomatic, occurs in approximately 25 to 30 percent of patients. Risk factors for hyperammonemia include high valproate dose and plasma concentrations and concomitant use of enzyme-inducing antiseizure medications, carbonic anhydrase inhibitors, and antipsychotic drugs. (See  <a class="medical medical_review" href="/d/html/338.html" rel="external">"Valproic acid poisoning", section on 'Valproate-related hyperammonemic encephalopathy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute hepatocellular injury</strong> with jaundice can occur, usually within the first six months of starting <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>. In some cases this is associated with fulminant liver failure and death. Risk factors include age under two, polytherapy, and coexistent congenital metabolic disorders [<a href="#rid320">320,321</a>]. A Reye-like syndrome has been described in children who develop fever and lethargy followed by confusion, stupor and coma, raised ammonia levels, and marked ALT elevations. (See  <a class="medical medical_review" href="/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/16142.html" rel="external">"Acute liver failure in children: Etiology and evaluation"</a>.)</p><p></p><p class="bulletIndent2">Although routine monitoring of hepatic function has not been shown to permit early identification of serious toxicity or improve outcome, many clinicians choose to obtain LFTs once or twice a year in patients who are clinically asymptomatic. The FDA recommends checking LFTs prior to initiating treatment and at frequent intervals thereafter, especially during the first six months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute pancreatitis</strong> is a rare complication of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> therapy [<a href="#rid322">322,323</a>]. Symptoms (abdominal pain and vomiting) are similar to those from pancreatitis from other causes. Patients typically recover, but deaths have been reported. This adverse effect is idiosyncratic and is not related to dose or duration of therapy; rechallenge frequently results in relapse. (See  <a class="medical medical_review" href="/d/html/5640.html" rel="external">"Etiology of acute pancreatitis", section on 'Medications'</a>.)</p><p></p><p class="headingAnchor" id="H3652470985"><span class="h2">Vigabatrin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10115" href="/d/drug information/10115.html" rel="external">Vigabatrin</a> (VGB) is an irreversible inhibitor of GABA-T that raises the concentration of GABA in the central nervous system.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – It is effective as an add-on agent in patients with refractory focal seizures [<a href="#rid324">324</a>]. It is also useful as monotherapy [<a href="#rid325">325</a>], although probably less effective than <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> for this purpose [<a href="#rid326">326,327</a>]. Clinical observations also suggest that it may be particularly effective for infantile spasms in children with tuberous sclerosis. (See  <a class="medical medical_review" href="/d/html/6186.html" rel="external">"Infantile epileptic spasms syndrome: Management and prognosis", section on 'Vigabatrin'</a>.)</p><p></p><p class="bulletIndent1">VGB was approved by the FDA in 2009 for the treatment of infantile spasms and for adjunctive treatment of adults with refractory focal seizures. It is licensed in Canada and in many countries of Europe and Asia. Due to the associate risk of visual loss, VGB should be reserved for patients with epilepsy that is refractory to other drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="10115" href="/d/drug information/10115.html" rel="external">Vigabatrin</a> does not undergo hepatic metabolism but is a weak inducer of CYP2C9  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). It is eliminated without change in the urine. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – VGB is started at 500 mg twice daily and increased weekly in 500 mg increments to a total recommended dose of 3000 mg per day for adults age 17 years and older and 2000 mg per day for children age 10 to 16 years [<a href="#rid328">328</a>]. VGB is excreted renally, and dose adjustments are required in patients with renal insufficiency. Dosing for infantile spasms is reviewed separately. (See  <a class="medical medical_review" href="/d/html/6186.html" rel="external">"Infantile epileptic spasms syndrome: Management and prognosis", section on 'Vigabatrin'</a>.)</p><p></p><p class="bulletIndent1">Because of the FDA boxed warning in the United States about the risk of permanent vision loss, prescribers, patients, and pharmacies must participate in the Risk Evaluation and Mitigation Strategies (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.vigabatrinrems.com%2F%23Main&amp;token=5CnMhehlb6qiSCK80v48R%2FtLFrfQsf0aoYmIN1VSDcqjEMdTvbTH%2FosD2ygyn2Jj&amp;TOPIC_ID=2221" target="_blank">REMS</a>) program. Visual field testing should be performed before starting therapy and repeated every six months [<a href="#rid329">329,330</a>]. Optical coherence tomography may be useful to monitor vision in patients who are unable to perform visual field perimetry [<a href="#rid331">331</a>]. While animal studies suggest the possibility that reduced light exposure and dietary supplementation with taurine may ameliorate this adverse event, this has not been established in humans [<a href="#rid332">332</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Frequent adverse events with VGB include drowsiness, fatigue, headache, and dizziness [<a href="#rid326">326</a>]. Depression and weight gain can occur. Severe hypersensitivity reactions and angioedema have also been reported.</p><p></p><p class="bulletIndent1">A boxed warning for VGB alerts clinicians to safety concerns regarding permanent vision loss with this medication [<a href="#rid333">333</a>]. As many as 30 to 50 percent of adults with long-term exposure to VGB have developed irreversible concentric visual field loss of varying severity that is often asymptomatic [<a href="#rid334">334-339</a>]. A similar risk has been estimated in children, although studies are more limited [<a href="#rid340">340,341</a>]. Most studies have found that higher cumulative dose and male gender increase the risk of vision loss [<a href="#rid336">336,339,340,342,343</a>]. Visual field deficits have been noted as early as nine months after initiation of treatment, with a mean time to onset of approximately five years [<a href="#rid329">329</a>]. VGB treatment in laboratory rats is associated with irreversible injury of cone photoreceptors [<a href="#rid344">344</a>].</p><p></p><p class="bulletIndent1">VGB has also been reported to produce magnetic resonance imaging (MRI) abnormalities, specifically hyperintense lesions on T2-weighted images and/or restricted diffusion on diffusion-weighted imaging, which involve the basal ganglia, thalamus, brainstem, dentate nucleus of the cerebellum, anterior commissure, and hippocampus [<a href="#rid345">345-349</a>]. These abnormalities are usually bilateral and symmetric. They occur primarily in infants and only in those who are treated for infantile spasms and seem to be a dose-related phenomenon. The prevalence is 22 to 47 percent [<a href="#rid345">345,346,348,350</a>]. These abnormalities are not clearly associated with new neurologic deficits and normalize when VGB is discontinued [<a href="#rid345">345,346,349</a>]. In a few cases, they have been observed to resolve even while VGB was continued.</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Zonisamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">Zonisamide</a> is a sulfonamide derivative that is chemically and structurally unrelated to other antiseizure medications. Its primary mechanism of action appears to be to blocking both voltage-dependent sodium and T-type calcium channels.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">Zonisamide</a> is a broad-spectrum agent that has been proven effective in randomized, controlled trials as add-on therapy for both focal and generalized seizures in adults and children [<a href="#rid351">351,352</a>]. Zonisamide also has activity in myoclonic epilepsy. Observational studies and one randomized noninferiority trial with a comparison with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> suggest that it is effective in monotherapy as well [<a href="#rid353">353-356</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism and interactions</strong> – <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">Zonisamide</a> is metabolized primarily in the liver by CYP and non-CYP transformations but is not a CYP inducer  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>). Dose adjustments are needed for mild renal or hepatic insufficiency, and the drug is not recommended in patients with moderate or severe renal insufficiency.</p><p></p><p class="bulletIndent1">Drug interactions are limited; however, clearance may be increased when used with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, or <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> [<a href="#rid357">357</a>]. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The recommended initial daily dose is 100 to 200 mg per day in two divided doses. Because of its long half-life, once-a-day dosing is often effective. The dose is increased at two-week intervals to a target maintenance dose of 400 to 600 mg per day, although higher doses may be necessary in some patients. Adjustments of <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a> dose may be required when <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, or <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> are added or removed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most commonly reported side effects of <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a> are somnolence, ataxia, anorexia, confusion, abnormal thinking, nervousness, fatigue, and dizziness; in children, decreased sweating and fever have been reported  (<a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/d/graphic/59755.html" rel="external">table 5A-B</a>). Most of these are self-limited, and the likelihood of adverse effects can be reduced by gradually titrating the dose over four to eight weeks. However, in one study, cognitive deficits associated with initiation of zonisamide treatment were dose related and persisted one year after treatment was started [<a href="#rid358">358</a>]. In another study, cognitive and psychiatric side effects (including depression, psychosis, and aggression) led to discontinuation of zonisamide in 5.8 and 6.9 percent of patients, respectively [<a href="#rid359">359</a>]. A past history of psychiatric symptoms and symptomatic generalized epilepsy were risk factors for psychiatric side effects.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">Zonisamide</a> is a weak carbonic anhydrase inhibitor. Nephrolithiasis was reported in 4 percent of patients in an early clinical trial, but later studies found a much lower risk [<a href="#rid360">360</a>]. (See  <a class="medical medical_review" href="/d/html/2369.html" rel="external">"Nephrolithiasis in renal tubular acidosis", section on 'Carbonic anhydrase inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H1900943684"><span class="h1">ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H1780224909"><span class="h2">Common adverse effects</span><span class="headingEndMark"> — </span>Common adverse effects of antiseizure medications are summarized in the table  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5A</a>) and reviewed individually for each of the antiseizure medications listed above. (See <a class="local">'Antiseizure medications'</a> above.)</p><p class="headingAnchor" id="H4199249770"><span class="h2">Hyponatremia</span><span class="headingEndMark"> — </span>Hyponatremia is a well-described adverse effect of both <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, due at least in part to increased responsiveness of collecting tubules to antidiuretic hormone. It has also been observed with <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">eslicarbazepine</a>. It is considered to be one of the forms of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). (See  <a class="medical medical_review" href="/d/html/2384.html" rel="external">"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)", section on 'Drugs'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency</strong> – The reported prevalence of oxcarbazepine- and carbamazepine-induced hyponatremia varies widely, in part due to differences in the threshold used to define hyponatremia and differences in study populations. Estimates range from approximately 25 to 75 percent for <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> and from 5 to 40 percent for <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> [<a href="#rid361">361-367</a>]. In one large cohort study of nearly 1500 patients with epilepsy taking either drug, rates of any hyponatremia (sodium ≤134 mEq/L) among those taking oxcarbazepine and carbamazepine were 48 and 26 percent, respectively [<a href="#rid366">366</a>]. Rates of severe hyponatremia (sodium ≤128 mEq/L) were 22 and 7 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for hyponatremia appear to be similar for <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and include older age, high serum levels of carbamazepine or oxcarbazepine, antiseizure medication polytherapy, concomitant antihypertensive medications, especially diuretics, and a history of hyponatremia with prior exposure to either drug [<a href="#rid366">366,367</a>].</p><p></p><p class="bulletIndent1">A clear dose response relationship between <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> and hyponatremia has not been established, and data are conflicting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manifestations</strong> – Hyponatremia may develop gradually over the first few months of therapy, and many patients are asymptomatic [<a href="#rid368">368</a>]. Although symptoms attributable to hyponatremia are to some degree related to the severity of the abnormality, the rate of onset is of primary importance. Acute or severe hyponatremia can cause cerebral edema, which can lead to lethargy, encephalopathy, headaches, and seizures. Because of a cerebral adaptation, the degree of cerebral edema is less with chronic hyponatremia, and most patients seem to be asymptomatic. (See  <a class="medical medical_review" href="/d/html/2287.html" rel="external">"Manifestations of hyponatremia and hypernatremia in adults"</a>.)</p><p></p><p class="bulletIndent1">Oxcarbazepine-related hyponatremia tends to be mild, asymptomatic, and reversible, and overall tolerability of <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> appears to be better than that of carbamazepine-related hyponatremia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Measurement of serum sodium concentration is recommended prior to initiation of <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> therapy and again once the patient reaches a therapeutic dose. Serum sodium should be checked in patients on chronic therapy if the patient develops symptoms suggestive of hyponatremia (eg, lethargy, encephalopathy, headaches), especially in the presence of a predisposing factor such as renal failure or a central nervous system lesion that itself can cause SIADH. (See  <a class="medical medical_review" href="/d/html/2374.html" rel="external">"Causes of hypotonic hyponatremia in adults"</a>.)</p><p></p><p class="bulletIndent1">Cessation of <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> therapy because of hyponatremia is uncommon, being required in only 1 percent of patients in a postmarketing study. Mild to moderate asymptomatic hyponatremia can typically be managed with fluid restriction with or without increased salt intake. Patients who cannot comply with fluid restriction and have severe or symptomatic hyponatremia should be transitioned to an alternative antiseizure medication. (See  <a class="medical medical_review" href="/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat"</a>.)</p><p></p><p class="headingAnchor" id="H315923232"><span class="h2">Bone disease</span><span class="headingEndMark"> — </span>Patients with epilepsy are at higher risk for bone disease because of a higher risk for falls and physical trauma related to seizures themselves, the neurologic disease that underlies the epilepsy (eg, stroke, cerebral palsy), and the effects of certain antiseizure medications that impair gait stability and alter bone and mineral metabolism. These issues are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/2063.html" rel="external">"Antiseizure medications and bone disease"</a>.)</p><p class="headingAnchor" id="H4243191569"><span class="h2">Severe adverse reactions</span><span class="headingEndMark"> — </span>Rare but serious adverse effects of antiseizure medications are summarized in the table  (<a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 5B</a>). Some severe reactions that are common to more than one antiseizure medication include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suicidality</strong> – As a class, antiseizure medications have been associated with an increased risk of suicidal ideation and suicidal behavior [<a href="#rid369">369</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SJS, TEN, and DRESS</strong> – Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) are rare but severe idiosyncratic reactions that have been associated with the use of <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">primidone</a>, <a class="drug drug_general" data-topicid="9862" href="/d/drug information/9862.html" rel="external">zonisamide</a>, and (less commonly) other antiseizure medications. (See  <a class="medical medical_review" href="/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a>.)</p><p></p><p class="headingAnchor" id="H3242513"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic profiles of antiseizure medications</strong> – While sharing a common property of suppressing epileptic seizures, antiseizure medications have many different pharmacologic profiles that are relevant when selecting and prescribing these agents in patients with epilepsy and other conditions. These include pharmacokinetic properties and propensity for drug-drug interactions, as well as side effect profiles and toxicities. (See <a class="local">'Pharmacologic profiles'</a> above.)</p><p></p><p class="bulletIndent1">For drug-specific summaries, refer to the specific drug headings above. Summaries of different properties are also listed in the tables:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known or suspected mechanism of action  (<a class="graphic graphic_table graphicRef71274" href="/d/graphic/71274.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Important pharmacologic properties  (<a class="graphic graphic_table graphicRef60182" href="/d/graphic/60182.html" rel="external">table 3</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some important drug interactions  (<a class="graphic graphic_table graphicRef80801" href="/d/graphic/80801.html" rel="external">table 4A</a> and <a class="graphic graphic_table graphicRef55399" href="/d/graphic/55399.html" rel="external">table 4B</a> and <a class="graphic graphic_table graphicRef53463" href="/d/graphic/53463.html" rel="external">table 4C</a> and <a class="graphic graphic_table graphicRef54244" href="/d/graphic/54244.html" rel="external">table 6</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial selection of antiseizure medication</strong> – A discussion of antiseizure medication selection in specific patient situations is presented separately. (See  <a class="medical medical_review" href="/d/html/2212.html" rel="external">"Initial treatment of epilepsy in adults", section on 'Selection of an antiseizure medication'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common and rare adverse effects of antiseizure medications are listed in the tables  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 5A</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 5B</a>). While most antiseizure medications are potentially effective against focal seizures and generalized convulsive seizures (<a class="drug drug_general" data-topicid="9440" href="/d/drug information/9440.html" rel="external">ethosuximide</a> is a notable exception), some also have the potential to worsen certain generalized seizure types (eg, absence seizures, myoclonic seizures)  (<a class="graphic graphic_table graphicRef78021" href="/d/graphic/78021.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef106663" href="/d/graphic/106663.html" rel="external">table 7</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">Oxcarbazepine</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="91586" href="/d/drug information/91586.html" rel="external">eslicarbazepine</a> may cause hyponatremia. (See <a class="local">'Hyponatremia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with epilepsy are at higher risk for bone disease, due in part to the effects of certain antiseizure medications that impair gait stability and alter bone and mineral metabolism. These issues are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/2063.html" rel="external">"Antiseizure medications and bone disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiseizure medications as a class have been associated with an increased risk of suicidal ideation and suicidal behavior. Certain antiseizure medications are associated with a risk of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). (See <a class="local">'Severe adverse reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Detailed prescribing information</strong> – For detailed prescribing information, readers should refer to the individual drug information topics within UpToDate. Comprehensive information on drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Coulter DA, Huguenard JR, Prince DA. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett 1989; 98:74.</a></li><li><a class="nounderline abstract_t">Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11:56.</a></li><li><a class="nounderline abstract_t">Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol 2020; 19:544.</a></li><li><a class="nounderline abstract_t">Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2016; 57:201.</a></li><li><a class="nounderline abstract_t">Yang X, Bognar J Jr, He T, et al. Brivaracetam augments short-term depression and slows vesicle recycling. Epilepsia 2015; 56:1899.</a></li><li><a class="nounderline abstract_t">Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015; 56:1890.</a></li><li><a class="nounderline abstract_t">Tian X, Yuan M, Zhou Q, Wang X. The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies. Expert Opin Pharmacother 2015; 16:1755.</a></li><li><a class="nounderline abstract_t">Ma J, Huang S, You C. Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials. Epilepsy Res 2015; 114:59.</a></li><li><a class="nounderline abstract_t">Toledo M, Whitesides J, Schiemann J, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia 2016; 57:1139.</a></li><li><a class="nounderline abstract_t">Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014; 55:38.</a></li><li><a class="nounderline abstract_t">Kälviäinen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies. Epilepsia 2016; 57:210.</a></li><li><a class="nounderline abstract_t">Hagemann A, Klimpel D, Bien CG, et al. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy. Epilepsia 2020; 61:e43.</a></li><li class="breakAll">Briviact (brivaracetam) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205836s009,205837s007,205838s006lbl.pdf (Accessed on September 20, 2021).</li><li><a class="nounderline abstract_t">Klein P, Biton V, Dilley D, et al. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy. Epilepsia 2016; 57:1130.</a></li><li><a class="nounderline abstract_t">Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. Epilepsy Behav 2021; 118:107939.</a></li><li><a class="nounderline abstract_t">Steinig I, von Podewils F, Möddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. Epilepsia 2017; 58:1208.</a></li><li><a class="nounderline abstract_t">Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018; 84:2477.</a></li><li class="breakAll">Epidiolex (cannabidiol) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210365Orig1s011lbl.pdf (Accessed on August 26, 2022).</li><li><a class="nounderline abstract_t">Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54:551.</a></li><li><a class="nounderline abstract_t">Powell G, Saunders M, Rigby A, Marson AG. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev 2016; 12:CD007124.</a></li><li><a class="nounderline abstract_t">Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008; 71:1527.</a></li><li><a class="nounderline abstract_t">Herzog AG, Drislane FW, Schomer DL, et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 2005; 65:1016.</a></li><li><a class="nounderline abstract_t">Lossius MI, Taubøll E, Mowinckel P, et al. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy--a prospective randomized double-blind withdrawal study. Epilepsia 2007; 48:1875.</a></li><li><a class="nounderline abstract_t">Aggarwal A, Rastogi N, Mittal H, et al. Thyroid hormone levels in children receiving carbamazepine or valproate. Pediatr Neurol 2011; 45:159.</a></li><li><a class="nounderline abstract_t">Verrotti A, Laus M, Scardapane A, et al. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 2009; 160:81.</a></li><li><a class="nounderline abstract_t">Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353:2190.</a></li><li><a class="nounderline abstract_t">Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007; 68:1701.</a></li><li><a class="nounderline abstract_t">Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP 1990; 24:1214.</a></li><li class="breakAll">FDA approves new treatment for adults with partial-onset seizures. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures (Accessed on January 10, 2020).</li><li><a class="nounderline abstract_t">Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol 2020; 19:38.</a></li><li><a class="nounderline abstract_t">Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology 2020; 94:e2311.</a></li><li class="breakAll">Xcopri (cenobamate tablets) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf (Accessed on January 09, 2020).</li><li><a class="nounderline abstract_t">Abou-Khalil BW. Antiepileptic Drugs. Continuum (Minneap Minn) 2016; 22:132.</a></li><li class="breakAll">Onfi (clobazam) prescribing information. https://www.lundbeck.com/upload/us/files/pdf/Products/ONFI_PI_US_EN.pdf (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">Klehm J, Thome-Souza S, Sánchez Fernández I, et al. Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. Pediatr Neurol 2014; 51:60.</a></li><li><a class="nounderline abstract_t">Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50:1158.</a></li><li><a class="nounderline abstract_t">Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77:1473.</a></li><li><a class="nounderline abstract_t">Manyas H, Paketci C, Okur D, et al. A Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Clobazam. Pediatr Emerg Care 2020; 36:e175.</a></li><li class="breakAll">Summary Safety Review - Clobazam-containing products - Health Canada - Assessing the Potential Risk of Drug Reaction with Eosinophilia and Systemic Symptoms. https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00251 (Accessed on December 11, 2020).</li><li class="breakAll">FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan). Available at: https://www.fda.gov/media/174157/download?attachment (Accessed on January 09, 2024).</li><li><a class="nounderline abstract_t">Brigo F, Igwe SC, Bragazzi NL, Lattanzi S. Clonazepam monotherapy for treating people with newly diagnosed epilepsy. Cochrane Database Syst Rev 2019; 2019.</a></li><li><a class="nounderline abstract_t">Keränen T, Sivenius J. Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. Acta Neurol Scand Suppl 1983; 97:69.</a></li><li><a class="nounderline abstract_t">Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999; 42:2582.</a></li><li><a class="nounderline abstract_t">Chang XC, Yuan H, Wang Y, et al. Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev 2021; 6:CD008907.</a></li><li><a class="nounderline abstract_t">Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia 2015; 56:244.</a></li><li><a class="nounderline abstract_t">Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013; 52:927.</a></li><li class="breakAll">Aptiom (eslicarbazepine acetate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022416s009lbl.pdf (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet 2013; 52:1045.</a></li><li><a class="nounderline abstract_t">Vaz-da-Silva M, Almeida L, Falcão A, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther 2010; 32:179.</a></li><li><a class="nounderline abstract_t">Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989; 25:582.</a></li><li><a class="nounderline abstract_t">Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362:790.</a></li><li><a class="nounderline abstract_t">Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol 1994; 35:229.</a></li><li><a class="nounderline abstract_t">Troupin AS, Montouris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy 1997; 10:26.</a></li><li><a class="nounderline abstract_t">Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328:29.</a></li><li><a class="nounderline abstract_t">Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993; 34 Suppl 7:S18.</a></li><li><a class="nounderline abstract_t">Egnell AC, Houston B, Boyer S. In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 2003; 305:1251.</a></li><li><a class="nounderline abstract_t">Wagner ML, Graves NM, Leppik IE, et al. The effect of felbamate on valproic acid disposition. Clin Pharmacol Ther 1994; 56:494.</a></li><li><a class="nounderline abstract_t">Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia 1999; 40:1122.</a></li><li><a class="nounderline abstract_t">van Hooft JA, Dougherty JJ, Endeman D, et al. Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002; 449:221.</a></li><li><a class="nounderline abstract_t">Bryans JS, Davies N, Gee NS, et al. Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents. J Med Chem 1998; 41:1838.</a></li><li><a class="nounderline abstract_t">Belliotti TR, Capiris T, Ekhato IV, et al. Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. J Med Chem 2005; 48:2294.</a></li><li><a class="nounderline abstract_t">Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2018; 91:82.</a></li><li><a class="nounderline abstract_t">Panebianco M, Al-Bachari S, Hutton JL, Marson AG. Gabapentin add-on treatment for drug-resistant focal epilepsy. Cochrane Database Syst Rev 2021; 1:CD001415.</a></li><li><a class="nounderline abstract_t">Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2018; 91:74.</a></li><li class="breakAll">Neurontin (gabapentin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206030s000lbl.pdf (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res 1998; 31:91.</a></li><li><a class="nounderline abstract_t">The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group. Epilepsy Res 1994; 18:67.</a></li><li><a class="nounderline abstract_t">Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med 2010; 123:367.</a></li><li><a class="nounderline abstract_t">Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016; 111:1160.</a></li><li><a class="nounderline abstract_t">Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs 2017; 77:403.</a></li><li><a class="nounderline abstract_t">Kuehn BM. Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices. JAMA 2022; 328:1283.</a></li><li><a class="nounderline abstract_t">In brief: Respiratory depression with gabapentinoids. Med Lett Drugs Ther 2020; 62:81.</a></li><li><a class="nounderline abstract_t">Tambon M, Montarnal B, Lepetit M, Lapeyre-Mestre M. Non-opioid antinociceptive drugs : risk of respiratory depression and death related to concomitant use of gabapentinoids in addition to opioids. Expert Opin Drug Saf 2023; 22:183.</a></li><li><a class="nounderline abstract_t">Rahman AA, Dell'Aniello S, Moodie EEM, et al. Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease : A Population-Based Cohort Study. Ann Intern Med 2024.</a></li><li><a class="nounderline abstract_t">Perucca E, Yasothan U, Clincke G, Kirkpatrick P. Lacosamide. Nat Rev Drug Discov 2008; 7:973.</a></li><li><a class="nounderline abstract_t">Holtkamp D, Opitz T, Niespodziany I, et al. Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na(+) channel inactivation. Epilepsia 2017; 58:27.</a></li><li class="breakAll">Vimpat (lacosamide) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022253s050,022254s040,022255s032lbl.pdf (Accessed on May 17, 2023).</li><li><a class="nounderline abstract_t">Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50:443.</a></li><li><a class="nounderline abstract_t">Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51:958.</a></li><li><a class="nounderline abstract_t">Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48:1308.</a></li><li><a class="nounderline abstract_t">Babar RK, Bresnahan R, Gillespie CS, Michael BD. Lacosamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev 2021; 5:CD008841.</a></li><li><a class="nounderline abstract_t">Husain A, Chung S, Faught E, et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia 2012; 53:521.</a></li><li><a class="nounderline abstract_t">Guilhoto LM, Loddenkemper T, Gooty VD, et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011; 44:414.</a></li><li><a class="nounderline abstract_t">Rastogi RG, Ng YT. Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol 2012; 27:492.</a></li><li><a class="nounderline abstract_t">Yorns WR Jr, Khurana DS, Carvalho KS, et al. Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy. J Child Neurol 2014; 29:23.</a></li><li><a class="nounderline abstract_t">Pasha I, Kamate M, Didagi SK. Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy. Pediatr Neurol 2014; 51:509.</a></li><li><a class="nounderline abstract_t">Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia 2014; 55:1088.</a></li><li class="breakAll">Motpoly XR (lacosamide) extended-release capsules, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216185s000lbl.pdf (Accessed on May 17, 2023).</li><li><a class="nounderline abstract_t">Larsen Burns M, Nikanorova M, Baftiu A, et al. Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway. Ther Drug Monit 2019; 41:340.</a></li><li><a class="nounderline abstract_t">May TW, Helmer R, Bien CG, Brandt C. Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages. Ther Drug Monit 2018; 40:620.</a></li><li><a class="nounderline abstract_t">Zaccara G, Perucca P, Loiacono G, et al. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2013; 54:66.</a></li><li><a class="nounderline abstract_t">Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011; 20:20.</a></li><li><a class="nounderline abstract_t">Cuzzola A, Ferlazzo E, Italiano D, et al. Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases. Epilepsy Behav 2010; 19:650.</a></li><li><a class="nounderline abstract_t">Nizam A, Mylavarapu K, Thomas D, et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia 2011; 52:e153.</a></li><li><a class="nounderline abstract_t">Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010; 18:322.</a></li><li><a class="nounderline abstract_t">Huberman MA, Mallar C, Kalika PM. Neonatal Cardiac Arrest Following Lacosamide Treatment: A Case Report. Pediatr Neurol 2023; 149:184.</a></li><li><a class="nounderline abstract_t">Lee CY, Fu WM, Chen CC, et al. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 2008; 49:888.</a></li><li><a class="nounderline abstract_t">Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65:1737.</a></li><li><a class="nounderline abstract_t">Biton V, Di Memmo J, Shukla R, et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav 2010; 19:352.</a></li><li><a class="nounderline abstract_t">Ramaratnam S, Panebianco M, Marson AG. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2016; :CD001909.</a></li><li><a class="nounderline abstract_t">Piña-Garza JE, Levisohn P, Gucuyener K, et al. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology 2008; 70:2099.</a></li><li><a class="nounderline abstract_t">Piña-Garza JE, Elterman RD, Ayala R, et al. Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old. J Child Neurol 2008; 23:853.</a></li><li><a class="nounderline abstract_t">Arif H, Svoronos A, Resor SR Jr, et al. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia 2011; 52:1905.</a></li><li><a class="nounderline abstract_t">Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005; 46:1414.</a></li><li><a class="nounderline abstract_t">Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47:1447.</a></li><li><a class="nounderline abstract_t">O'Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 2006; 47:1419.</a></li><li><a class="nounderline abstract_t">Contin M, Albani F, Ambrosetto G, et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 2006; 47:1573.</a></li><li><a class="nounderline abstract_t">Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007; 48:484.</a></li><li><a class="nounderline abstract_t">Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009; 72:911.</a></li><li><a class="nounderline abstract_t">Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009; 73:1388.</a></li><li class="breakAll">WHO Medical eligibility criteria for contraceptive use. Fourth edition, 2009. http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf. (Accessed on June 11, 2012).</li><li><a class="nounderline abstract_t">Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59:251.</a></li><li><a class="nounderline abstract_t">de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63:571.</a></li><li><a class="nounderline abstract_t">Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006; 67:1297.</a></li><li><a class="nounderline abstract_t">Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 2005; 62:1432.</a></li><li><a class="nounderline abstract_t">Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996; 31:309.</a></li><li class="breakAll">Lamictal (lamotrigine) prescribing information. Available at: https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/d7e3572d-56fe-4727-2bb4-013ccca22678/spl-doc? (Accessed on July 20, 2021).</li><li><a class="nounderline abstract_t">Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology 2007; 69:1610.</a></li><li><a class="nounderline abstract_t">Tompson DJ, Ali I, Oliver-Willwong R, et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia 2008; 49:410.</a></li><li><a class="nounderline abstract_t">Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63:1022.</a></li><li><a class="nounderline abstract_t">Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of Lamotrigine-associated rash. Epilepsia 2006; 47:318.</a></li><li><a class="nounderline abstract_t">Wang XQ, Lv B, Wang HF, et al. Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients. Clin Neurol Neurosurg 2015; 138:1.</a></li><li><a class="nounderline abstract_t">Ignaszewski M, Ignaszewski MJ, Kohlitz P. Lamotrigine-Associated Hemophagocytic Lymphohistiocytosis. Am J Ther 2017; 24:e493.</a></li><li class="breakAll">FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal). https://www.fda.gov/Drugs/DrugSafety/ucm605470.htm (Accessed on August 31, 2018).</li><li><a class="nounderline abstract_t">Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005; 65:762.</a></li><li><a class="nounderline abstract_t">Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 2006; 47:860.</a></li><li><a class="nounderline abstract_t">Dinnerstein E, Jobst BC, Williamson PD. Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy. Arch Neurol 2007; 64:1344.</a></li><li><a class="nounderline abstract_t">Simms KM, Kortepeter C, Avigan M. Lamotrigine and aseptic meningitis. Neurology 2012; 78:921.</a></li><li><a class="nounderline abstract_t">Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101:9861.</a></li><li><a class="nounderline abstract_t">Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 1999; 96:15268.</a></li><li><a class="nounderline abstract_t">Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006; 26:1303.</a></li><li><a class="nounderline abstract_t">Doelken MT, Hammen T, Bogner W, et al. Alterations of intracerebral γ-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies. Epilepsia 2010; 51:1477.</a></li><li><a class="nounderline abstract_t">Meehan AL, Yang X, Yuan LL, Rothman SM. Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia 2012; 53:469.</a></li><li><a class="nounderline abstract_t">Abou-Khalil BW. Update on Antiseizure Medications 2022. Continuum (Minneap Minn) 2022; 28:500.</a></li><li><a class="nounderline abstract_t">Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev 2012; :CD001901.</a></li><li><a class="nounderline abstract_t">Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 2001; 42 Suppl 4:31.</a></li><li><a class="nounderline abstract_t">Leppik IE, Biton V, Sander JW, Wieser HG. Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials. Epilepsia 2003; 44:1585.</a></li><li><a class="nounderline abstract_t">Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70:607.</a></li><li><a class="nounderline abstract_t">Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia 2012; 53:111.</a></li><li><a class="nounderline abstract_t">Piña-Garza JE, Nordli DR Jr, Rating D, et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 2009; 50:1141.</a></li><li><a class="nounderline abstract_t">Krief P, Li Kan, Maytal J. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. J Child Neurol 2008; 23:582.</a></li><li class="breakAll">Keppra (levetiracetam). European Medicines Agency. https://www.ema.europa.eu/en/documents/overview/keppra-epar-summary-public_en.pdf (Accessed on August 23, 2023).</li><li><a class="nounderline abstract_t">Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69:1751.</a></li><li><a class="nounderline abstract_t">Ben-Menachem E. Preliminary efficacy of levetiracetam in monotherapy. Epileptic Disord 2003; 5 Suppl 1:S51.</a></li><li><a class="nounderline abstract_t">Khurana DS, Kothare SV, Valencia I, et al. Levetiracetam monotherapy in children with epilepsy. Pediatr Neurol 2007; 36:227.</a></li><li><a class="nounderline abstract_t">Kharel S, Ojha R, Khanal S. Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta-analysis. Brain Behav 2022; 12:e2779.</a></li><li><a class="nounderline abstract_t">Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev 2017; 6:CD011412.</a></li><li><a class="nounderline abstract_t">Tabrizi N, Zarvani A, Rezaei P, et al. Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial. Epilepsy Res 2019; 157:106214.</a></li><li><a class="nounderline abstract_t">Campos MSA, Ayres LR, Morelo MRS, et al. Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses. Int J Clin Pharm 2018; 40:589.</a></li><li><a class="nounderline abstract_t">Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 2004; 63:568.</a></li><li><a class="nounderline abstract_t">Depondt C, Yuen AW, Bell GS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2006; 77:101.</a></li><li><a class="nounderline abstract_t">Glass GA, Stankiewicz J, Mithoefer A, et al. Levetiracetam for seizures after liver transplantation. Neurology 2005; 64:1084.</a></li><li><a class="nounderline abstract_t">Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 2007; 48:2111.</a></li><li><a class="nounderline abstract_t">Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007; 48:1351.</a></li><li><a class="nounderline abstract_t">French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005; 46:324.</a></li><li><a class="nounderline abstract_t">Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9:80.</a></li><li><a class="nounderline abstract_t">Koubeissi MZ, Amina S, Pita I, et al. Tolerability and efficacy of oral loading of levetiracetam. Neurology 2008; 70:2166.</a></li><li><a class="nounderline abstract_t">Chhun S, Jullien V, Rey E, et al. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 2009; 50:1150.</a></li><li><a class="nounderline abstract_t">Goraya JS, Khurana DS, Valencia I, et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008; 38:177.</a></li><li><a class="nounderline abstract_t">Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006; 47:1128.</a></li><li><a class="nounderline abstract_t">Baulac M, Brodie MJ, Elger CE, et al. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia 2007; 48:589.</a></li><li><a class="nounderline abstract_t">Peltola J, Coetzee C, Jiménez F, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia 2009; 50:406.</a></li><li><a class="nounderline abstract_t">Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat 2009; 5:467.</a></li><li><a class="nounderline abstract_t">Richy FF, Banerjee S, Brabant Y, Helmers S. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques. Epilepsy Behav 2009; 16:240.</a></li><li><a class="nounderline abstract_t">Egunsola O, Choonara I, Sammons HM. Safety of Levetiracetam in Paediatrics: A Systematic Review. PLoS One 2016; 11:e0149686.</a></li><li><a class="nounderline abstract_t">Romoli M, Perucca E, Sen A. Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review. Epilepsy Behav 2020; 103:106861.</a></li><li><a class="nounderline abstract_t">Hurtado B, Koepp MJ, Sander JW, Thompson PJ. The impact of levetiracetam on challenging behavior. Epilepsy Behav 2006; 8:588.</a></li><li><a class="nounderline abstract_t">Helmstaedter C, Fritz NE, Kockelmann E, et al. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav 2008; 13:535.</a></li><li><a class="nounderline abstract_t">de la Loge C, Hunter SJ, Schiemann J, Yang H. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010; 18:291.</a></li><li><a class="nounderline abstract_t">Kawai M, Goji H, Kanemoto K. Aggression as psychiatric side effect of newer AEDs in patients with epilepsy: Cross-sectional study based on Buss-Perry Aggression Questionnaire. Epilepsy Behav 2021; 115:107546.</a></li><li><a class="nounderline abstract_t">Szucs A, Clemens Z, Jakus R, et al. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. Epilepsia 2008; 49:1174.</a></li><li><a class="nounderline abstract_t">Gelisse P, Juntas-Morales R, Genton P, et al. Dramatic weight loss with levetiracetam. Epilepsia 2008; 49:308.</a></li><li><a class="nounderline abstract_t">Hadjikoutis S, Pickersgill TP, Smith PE. Drug points: Weight loss associated with levetiracetam. BMJ 2003; 327:905.</a></li><li><a class="nounderline abstract_t">Cramer JA, Leppik IE, Rue KD, et al. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003; 56:135.</a></li><li><a class="nounderline abstract_t">Sahaya K, Goyal MK, Sarwal A, Singh NN. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia 2010; 51:2492.</a></li><li><a class="nounderline abstract_t">Meschede A, Runge U, Sabolek M. Thrombocytopenia during levetiracetam therapy. Epilepsy Res 2008; 80:91.</a></li><li><a class="nounderline abstract_t">Kimland E, Höjeberg B, von Euler M. Levetiracetam-induced thrombocytopenia. Epilepsia 2004; 45:877.</a></li><li class="breakAll">Trileptal (oxcarbazepine) prescribing information. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/trileptal.pdf (Accessed on January 17, 2020).</li><li><a class="nounderline abstract_t">Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev 2009; :CD006453.</a></li><li><a class="nounderline abstract_t">Nevitt SJ, Tudur Smith C, Marson AG. Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev 2018; 10:CD003615.</a></li><li><a class="nounderline abstract_t">Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005; 65:1370.</a></li><li><a class="nounderline abstract_t">Buggy Y, Layton D, Fogg C, Shakir SA. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia 2010; 51:818.</a></li><li><a class="nounderline abstract_t">Cansu A, Serdaroğlu A, Camurdan O, et al. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 2006; 47:1855.</a></li><li><a class="nounderline abstract_t">Vainionpää LK, Mikkonen K, Rättyä J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004; 45:197.</a></li><li><a class="nounderline abstract_t">Hu FY, Wu XT, An DM, et al. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population. Seizure 2011; 20:160.</a></li><li><a class="nounderline abstract_t">Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11:349.</a></li><li><a class="nounderline abstract_t">Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 2017; 88:78.</a></li><li><a class="nounderline abstract_t">Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010; 92:89.</a></li><li class="breakAll">Fycompa (perampanel) prescribing information. https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79:589.</a></li><li><a class="nounderline abstract_t">Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78:1408.</a></li><li><a class="nounderline abstract_t">French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013; 54:117.</a></li><li><a class="nounderline abstract_t">Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013; 54:1481.</a></li><li><a class="nounderline abstract_t">Gidal BE, Laurenza A, Hussein Z, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology 2015; 84:1972.</a></li><li><a class="nounderline abstract_t">French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology 2015; 85:950.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Gil-Nagel A, Wheless JW, et al. Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence. Epilepsy Behav 2022; 136:108885.</a></li><li><a class="nounderline abstract_t">Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia 2015; 56:12.</a></li><li><a class="nounderline abstract_t">Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia 2014; 55:1058.</a></li><li><a class="nounderline abstract_t">Leppik IE, Yang H, Williams B, et al. Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies. Epilepsia 2017; 58:51.</a></li><li><a class="nounderline abstract_t">Ettinger AB, LoPresti A, Yang H, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia 2015; 56:1252.</a></li><li><a class="nounderline abstract_t">Lagae L, Villanueva V, Meador KJ, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety. Epilepsia 2016; 57:1120.</a></li><li><a class="nounderline abstract_t">Datta AN, Xu Q, Sachedina S, et al. Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center. J Child Neurol 2017; 32:834.</a></li><li class="breakAll">Schedules of controlled substances: Placement of perampanel into Schedule III. Drug Enforcement Administration, US Department of Justice. https://www.deadiversion.usdoj.gov/fed_regs/rules/2013/fr1202.htm (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol 1986; 20:171.</a></li><li><a class="nounderline abstract_t">Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther 2014; 96:542.</a></li><li><a class="nounderline abstract_t">Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55:688.</a></li><li><a class="nounderline abstract_t">Mikati M, Bassett N, Schachter S. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992; 33:359.</a></li><li><a class="nounderline abstract_t">Burkhardt RT, Leppik IE, Blesi K, et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004; 63:1494.</a></li><li><a class="nounderline abstract_t">Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49:2087.</a></li><li><a class="nounderline abstract_t">Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50:1.</a></li><li><a class="nounderline abstract_t">Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271:5768.</a></li><li><a class="nounderline abstract_t">Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42:229.</a></li><li><a class="nounderline abstract_t">Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003; 12:663.</a></li><li><a class="nounderline abstract_t">Antinew J, Pitrosky B, Knapp L, et al. Pregabalin as Adjunctive Treatment for Focal Onset Seizures in Pediatric Patients: A Randomized Controlled Trial. J Child Neurol 2019; 34:248.</a></li><li><a class="nounderline abstract_t">Panebianco M, Bresnahan R, Hemming K, Marson AG. Pregabalin add-on for drug-resistant focal epilepsy. Cochrane Database Syst Rev 2019; 7:CD005612.</a></li><li><a class="nounderline abstract_t">Jan MM, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol 2009; 40:347.</a></li><li><a class="nounderline abstract_t">Kwan P, Brodie MJ, Kälviäinen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011; 10:881.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46:1407.</a></li><li><a class="nounderline abstract_t">Bockbrader HN, Burger P, Knapp L, Corrigan BW. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia 2011; 52:248.</a></li><li><a class="nounderline abstract_t">Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia 2011; 52:405.</a></li><li><a class="nounderline abstract_t">Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl 6:13.</a></li><li><a class="nounderline abstract_t">Feng MR, Turluck D, Burleigh J, et al. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet 2001; 26:123.</a></li><li><a class="nounderline abstract_t">Lee BI, Yi S, Hong SB, et al. Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia 2009; 50:464.</a></li><li><a class="nounderline abstract_t">Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs 2005; 19:265.</a></li><li><a class="nounderline abstract_t">Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45:20.</a></li><li><a class="nounderline abstract_t">Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64:475.</a></li><li><a class="nounderline abstract_t">Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 2010; 74:755.</a></li><li><a class="nounderline abstract_t">Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011; 52:826.</a></li><li><a class="nounderline abstract_t">Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42:790.</a></li><li><a class="nounderline abstract_t">Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70:1950.</a></li><li><a class="nounderline abstract_t">Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009; 14:491.</a></li><li><a class="nounderline abstract_t">Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010; 17:546.</a></li><li><a class="nounderline abstract_t">Thome-Souza S, Kadish NE, Ramgopal S, et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia 2014; 55:1235.</a></li><li><a class="nounderline abstract_t">Verrotti A, Loiacono G, Ballone E, et al. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol 2011; 44:347.</a></li><li><a class="nounderline abstract_t">Panebianco M, Prabhakar H, Marson AG. Rufinamide add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev 2020; 11:CD011772.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009; 50:1899.</a></li><li><a class="nounderline abstract_t">Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia 2011; 52:234.</a></li><li><a class="nounderline abstract_t">Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49:1123.</a></li><li><a class="nounderline abstract_t">Wheless JW, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24:1520.</a></li><li><a class="nounderline abstract_t">Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia 2011; 52 Suppl 2:76.</a></li><li><a class="nounderline abstract_t">Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997; 62:490.</a></li><li class="breakAll">Diacomit (stiripentol) prescribing information. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58304ba8-9779-4658-811e-94ffe08c3f16&amp;type=display (Accessed on August 19, 2022).</li><li><a class="nounderline abstract_t">Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356:1638.</a></li><li><a class="nounderline abstract_t">Guerrini R, Tonnelier S, d’Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia 2002; 43:155.</a></li><li><a class="nounderline abstract_t">Brigo F, Igwe SC, Bragazzi NL. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy. Cochrane Database Syst Rev 2017; 5:CD010483.</a></li><li class="breakAll">Diacomit (stiripentol) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf (Accessed on January 21, 2020).</li><li class="breakAll">Numis AL, Sankar R. Stiripentol. In: Pellock's pediatric epilepsy: diagnosis and therapy, 4th ed, Pellock JM, Nordli DR Jr, Sankar R, Wheless JW (Eds), Springer Publishing Company, New York 2017. p.897.</li><li><a class="nounderline abstract_t">Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia 2013; 54:1595.</a></li><li><a class="nounderline abstract_t">Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem 1990; 54:639.</a></li><li><a class="nounderline abstract_t">Pulman J, Hutton JL, Marson AG. Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2014; :CD001908.</a></li><li class="breakAll">Tiagabine prescribing information. https://www.tevausa.com/Pdf/Gabitril_PI.pdf (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">Aikiä M, Jutila L, Salmenperä T, et al. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia 2006; 47:1121.</a></li><li><a class="nounderline abstract_t">Jette N, Cappell J, VanPassel L, Akman CI. Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy. Neurology 2006; 67:1514.</a></li><li><a class="nounderline abstract_t">Flowers CM, Racoosin JA, Kortepeter C. Seizure activity and off-label use of tiagabine. N Engl J Med 2006; 354:773.</a></li><li><a class="nounderline abstract_t">Shinnar S, Berg AT, Treiman DM, et al. Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons. Epilepsia 2001; 42:372.</a></li><li><a class="nounderline abstract_t">Koepp MJ, Edwards M, Collins J, et al. Status epilepticus and tiagabine therapy revisited. Epilepsia 2005; 46:1625.</a></li><li class="breakAll">Topamax (topiramate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020505s064,020844s054lbl.pdf (Accessed on January 03, 2023).</li><li><a class="nounderline abstract_t">Pulman J, Jette N, Dykeman J, et al. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2014; :CD001417.</a></li><li><a class="nounderline abstract_t">Glauser TA, Dlugos DJ, Dodson WE, et al. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol 2007; 22:693.</a></li><li><a class="nounderline abstract_t">Novotny E, Renfroe B, Yardi N, et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 2010; 74:714.</a></li><li><a class="nounderline abstract_t">Sankar R, Ramsay E, McKay A, et al. A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice. Epilepsy Behav 2009; 15:506.</a></li><li><a class="nounderline abstract_t">Majkowski J, Neto W, Wapenaar R, Van Oene J. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia 2005; 46:648.</a></li><li><a class="nounderline abstract_t">Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009; 50:1072.</a></li><li><a class="nounderline abstract_t">de Carolis P, Magnifico F, Pierangeli G, et al. Transient hypohidrosis induced by topiramate. Epilepsia 2003; 44:974.</a></li><li><a class="nounderline abstract_t">Cerminara C, Seri S, Bombardieri R, et al. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol 2006; 34:392.</a></li><li><a class="nounderline abstract_t">Cirulli ET, Urban TJ, Marino SE, et al. Genetic and environmental correlates of topiramate-induced cognitive impairment. Epilepsia 2012; 53:e5.</a></li><li><a class="nounderline abstract_t">Salinsky MC, Storzbach D, Spencer DC, et al. Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 2005; 64:792.</a></li><li><a class="nounderline abstract_t">Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64:2108.</a></li><li><a class="nounderline abstract_t">Smith ME, Gevins A, McEvoy LK, et al. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia 2006; 47:695.</a></li><li><a class="nounderline abstract_t">Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006; 67:400.</a></li><li><a class="nounderline abstract_t">Aarsen FK, van den Akker EL, Drop SL, Catsman-Berrevoets CE. Effect of topiramate on cognition in obese children. Neurology 2006; 67:1307.</a></li><li><a class="nounderline abstract_t">Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology 2011; 76:131.</a></li><li><a class="nounderline abstract_t">Kang HC, Eun BL, Lee CW, et al. The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia 2007; 48:1716.</a></li><li><a class="nounderline abstract_t">Kim SJ, Kim MY, Choi YM, Song MK. Effects of topiramate on language functions in newly diagnosed pediatric epileptic patients. Pediatr Neurol 2014; 51:324.</a></li><li><a class="nounderline abstract_t">Coppola G, Verrotti A, Resicato G, et al. Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilepsy Behav 2008; 12:253.</a></li><li><a class="nounderline abstract_t">Chadwick D, Privitera M. How skeptical should we be about industry-sponsored studies? Neurology 2006; 67:378.</a></li><li><a class="nounderline abstract_t">Cho YJ, Heo K, Kim WJ, et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 2009; 50:1910.</a></li><li><a class="nounderline abstract_t">Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11:556.</a></li><li><a class="nounderline abstract_t">El Yaman SH, Mroueh SM, Sinno DD, Mikati MA. Long-term patterns of weight changes during topiramate therapy: an observational study. Neurology 2007; 69:310.</a></li><li><a class="nounderline abstract_t">Mukhin NA, Kozlovskaia LV, Bobkova IN, et al. [The key role of tubulointerstitium remodeling in progression of chronic renal diseases]. Arkh Patol 2004; 66:16.</a></li><li><a class="nounderline abstract_t">Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001; 42:387.</a></li><li><a class="nounderline abstract_t">Jovanović M, Sokić D, Grabnar I, et al. Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients. Ann Pharmacother 2014; 48:992.</a></li><li><a class="nounderline abstract_t">Kuo RL, Moran ME, Kim DH, et al. Topiramate-induced nephrolithiasis. J Endourol 2002; 16:229.</a></li><li class="breakAll">Important drug warning. Ortho-McNeil 2001. https://wayback.archive-it.org/7993/20170113165159/http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM173936.pdf (Accessed on January 20, 2020).</li><li><a class="nounderline abstract_t">Symes RJ, Etminan M, Mikelberg FS. Risk of angle-closure glaucoma with bupropion and topiramate. JAMA Ophthalmol 2015; 133:1187.</a></li><li><a class="nounderline abstract_t">Beyenburg S, Weyland C, Reuber M. Presumed topiramate-induced maculopathy. Epilepsy Behav 2009; 14:556.</a></li><li><a class="nounderline abstract_t">McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237:1001.</a></li><li><a class="nounderline abstract_t">Gram L. Experimental studies and controlled clinical testing of valproate and vigabatrin. Acta Neurol Scand 1988; 78:241.</a></li><li><a class="nounderline abstract_t">Löscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981; 30:1364.</a></li><li><a class="nounderline abstract_t">Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16:669.</a></li><li><a class="nounderline abstract_t">Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev 2017; 12:CD011412.</a></li><li><a class="nounderline abstract_t">Doré M, San Juan AE, Frenette AJ, Williamson D. Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia. Pharmacotherapy 2017; 37:900.</a></li><li><a class="nounderline abstract_t">Drozda K, Müller DJ, Bishop JR. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy 2014; 34:166.</a></li><li class="breakAll">Depacon (valproate sodium) for intravenous injection. https://www.rxabbvie.com/pdf/depacon.pdf (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55:722.</a></li><li><a class="nounderline abstract_t">Ramsay RE, Cantrell D, Collins SD, et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. Epilepsy Res 2003; 52:189.</a></li><li><a class="nounderline abstract_t">Wheless JW, Vazquez BR, Kanner AM, et al. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004; 63:1507.</a></li><li><a class="nounderline abstract_t">Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64:353.</a></li><li><a class="nounderline abstract_t">Limdi NA, Knowlton RK, Cofield SS, et al. Safety of rapid intravenous loading of valproate. Epilepsia 2007; 48:478.</a></li><li><a class="nounderline abstract_t">Rai A, Aggarwal A, Mittal H, Sharma S. Comparative efficacy and safety of intravenous valproate and phenytoin in children. Pediatr Neurol 2011; 45:300.</a></li><li><a class="nounderline abstract_t">Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56:172.</a></li><li><a class="nounderline abstract_t">Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007; 48:1366.</a></li><li><a class="nounderline abstract_t">Abaci A, Saygi M, Yis U, et al. Metabolic alterations during valproic acid treatment: a prospective study. Pediatr Neurol 2009; 41:435.</a></li><li><a class="nounderline abstract_t">Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010; 51:268.</a></li><li><a class="nounderline abstract_t">Esmael A, Elsherief M, Abdelsalam M, et al. Sleep Architecture in Valproate-Induced Nocturnal Enuresis in Primary School and Preschool Children. J Child Neurol 2020; 35:975.</a></li><li><a class="nounderline abstract_t">Gerstner T, Teich M, Bell N, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 2006; 47:1136.</a></li><li><a class="nounderline abstract_t">Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 2008; 49:438.</a></li><li><a class="nounderline abstract_t">Kumar R, Vidaurre J, Gedela S. Valproic Acid-Induced Coagulopathy. Pediatr Neurol 2019; 98:25.</a></li><li><a class="nounderline abstract_t">Castro-Gago M, Novo-Rodríguez MI, Gómez-Lado C, et al. Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs. Pediatr Neurol 2007; 37:426.</a></li><li><a class="nounderline abstract_t">Sahu JK, Gulati S, Kabra M, et al. Evaluation of subclinical hypothyroidism in ambulatory children with controlled epilepsy on valproate monotherapy. J Child Neurol 2012; 27:594.</a></li><li><a class="nounderline abstract_t">Sahota P, Prabhakar S, Kharbanda PS, et al. Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. Epilepsia 2008; 49:2069.</a></li><li><a class="nounderline abstract_t">Verrotti A, D'Egidio C, Mohn A, et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52:199.</a></li><li><a class="nounderline abstract_t">Endo A, Fujita Y, Fuchigami T, et al. Fanconi syndrome caused by valproic acid. Pediatr Neurol 2010; 42:287.</a></li><li><a class="nounderline abstract_t">Ristić AJ, Vojvodić N, Janković S, et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006; 47:2183.</a></li><li><a class="nounderline abstract_t">Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47:626.</a></li><li><a class="nounderline abstract_t">Easterford K, Clough P, Kellett M, et al. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004; 62:1435.</a></li><li><a class="nounderline abstract_t">Masmoudi K, Gras-Champel V, Masson H, Andréjak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006; 39:9.</a></li><li><a class="nounderline abstract_t">Jamora D, Lim SH, Pan A, et al. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord 2007; 22:130.</a></li><li><a class="nounderline abstract_t">Wu J, Li J, Jing W, et al. Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment. Epilepsy Behav 2021; 120:107967.</a></li><li><a class="nounderline abstract_t">Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379.</a></li><li><a class="nounderline abstract_t">Koenig SA, Buesing D, Longin E, et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006; 47:2027.</a></li><li><a class="nounderline abstract_t">Gerstner T, Büsing D, Bell N, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007; 42:39.</a></li><li><a class="nounderline abstract_t">Werlin SL, Fish DL. The spectrum of valproic acid-associated pancreatitis. Pediatrics 2006; 118:1660.</a></li><li><a class="nounderline abstract_t">Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 2013; :CD007302.</a></li><li><a class="nounderline abstract_t">Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996; 25:257.</a></li><li><a class="nounderline abstract_t">Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 354:13.</a></li><li><a class="nounderline abstract_t">Kälviäinen R, Aikiä M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52:989.</a></li><li><a class="nounderline abstract_t">Vigabatrin (Sabril) for epilepsy. Med Lett Drugs Ther 2010; 52:14.</a></li><li><a class="nounderline abstract_t">Willmore LJ, Abelson MB, Ben-Menachem E, et al. Vigabatrin: 2008 update. Epilepsia 2009; 50:163.</a></li><li><a class="nounderline abstract_t">Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 2001; 42:262.</a></li><li><a class="nounderline abstract_t">Clayton LM, Dévilé M, Punte T, et al. Retinal nerve fiber layer thickness in vigabatrin-exposed patients. Ann Neurol 2011; 69:845.</a></li><li><a class="nounderline abstract_t">Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009; 65:98.</a></li><li class="breakAll">Sabril (vigabatrin) prescribing information. https://www.lundbeck.com/upload/us/files/pdf/Products/sabril_PI_US_EN.pdf (Accessed on November 09, 2018).</li><li><a class="nounderline abstract_t">Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314:180.</a></li><li><a class="nounderline abstract_t">Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53:922.</a></li><li><a class="nounderline abstract_t">Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999; 53:2082.</a></li><li><a class="nounderline abstract_t">Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106:1792.</a></li><li><a class="nounderline abstract_t">Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001; 15:217.</a></li><li><a class="nounderline abstract_t">Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010; 51:2423.</a></li><li><a class="nounderline abstract_t">Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50:206.</a></li><li><a class="nounderline abstract_t">Riikonen R, Rener-Primec Z, Carmant L, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol 2015; 57:60.</a></li><li><a class="nounderline abstract_t">Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007; 48:1318.</a></li><li><a class="nounderline abstract_t">Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49:108.</a></li><li><a class="nounderline abstract_t">Duboc A, Hanoteau N, Simonutti M, et al. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 2004; 55:695.</a></li><li><a class="nounderline abstract_t">Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009; 50:184.</a></li><li><a class="nounderline abstract_t">Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50:195.</a></li><li><a class="nounderline abstract_t">Dracopoulos A, Widjaja E, Raybaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia 2010; 51:1297.</a></li><li><a class="nounderline abstract_t">Harini C, Yuskaitis CJ, Libenson MH, et al. Hippocampal Involvement With Vigabatrin-Related MRI Signal Abnormalities in Patients With Infantile Spasms: A Novel Finding. J Child Neurol 2021; 36:575.</a></li><li><a class="nounderline abstract_t">Tierradentro-García LO, Zandifar A, Stern J, et al. Magnetic Resonance Imaging-Based Distribution and Reversibility of Lesions in Pediatric Vigabatrin-Related Brain Toxicity. Pediatr Neurol 2023; 148:86.</a></li><li><a class="nounderline abstract_t">Xu Y, Wan L, He W, et al. Risk of vigabatrin-associated brain abnormalities on MRI: A retrospective and controlled study. Epilepsia 2022; 63:120.</a></li><li><a class="nounderline abstract_t">Guerrini R, Rosati A, Segieth J, et al. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia 2013; 54:1473.</a></li><li><a class="nounderline abstract_t">Brigo F, Lattanzi S, Igwe SC, et al. Zonisamide add-on therapy for focal epilepsy. Cochrane Database Syst Rev 2018; 10:CD001416.</a></li><li><a class="nounderline abstract_t">Tosches WA, Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006; 8:522.</a></li><li><a class="nounderline abstract_t">Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006; 34:351.</a></li><li><a class="nounderline abstract_t">Stephen LJ, Kelly K, Wilson EA, et al. A prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy Behav 2010; 17:455.</a></li><li><a class="nounderline abstract_t">Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012; 11:579.</a></li><li><a class="nounderline abstract_t">Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia 2007; 48:435.</a></li><li><a class="nounderline abstract_t">Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008; 12:102.</a></li><li><a class="nounderline abstract_t">White JR, Walczak TS, Marino SE, et al. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010; 75:513.</a></li><li><a class="nounderline abstract_t">LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291:605.</a></li><li><a class="nounderline abstract_t">Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65:1976.</a></li><li><a class="nounderline abstract_t">Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87:224.</a></li><li><a class="nounderline abstract_t">Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 2000; 54:2237.</a></li><li><a class="nounderline abstract_t">Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001; 21:904.</a></li><li><a class="nounderline abstract_t">Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003; 4:175.</a></li><li><a class="nounderline abstract_t">Berghuis B, van der Palen J, de Haan GJ, et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia 2017; 58:1227.</a></li><li><a class="nounderline abstract_t">Kim YS, Kim DW, Jung KH, et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. Seizure 2014; 23:208.</a></li><li><a class="nounderline abstract_t">Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001; 104:167.</a></li><li><a class="nounderline abstract_t">Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia 2013; 54:199.</a></li></ol></div><div id="topicVersionRevision">Topic 2221 Version 117.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2710401" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21686307" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Revisiting AMPA receptors as an antiepileptic drug target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109411" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 30 years of second-generation antiseizure medications: impact and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26663401" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26515103" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Brivaracetam augments short-term depression and slows vesicle recycling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26471380" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26165169" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088886" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265725" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24116853" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26666500" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304097" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304097" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Influence of dose and antiepileptic comedication on brivaracetam serum concentrations in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27221208" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33839453" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28480518" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30001569" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The pharmacokinetics and the pharmacodynamics of cannabinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30001569" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The pharmacokinetics and the pharmacodynamics of cannabinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23350722" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27933615" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981374" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cross-sensitivity of skin rashes with antiepileptic drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16217052" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555526" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy--a prospective randomized double-blind withdrawal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21824562" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Thyroid hormone levels in children receiving carbamazepine or valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984773" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392983" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502552" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison and predictors of rash associated with 15 antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2089834" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A review of carbamazepine's hematologic reactions and monitoring recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2089834" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A review of carbamazepine's hematologic reactions and monitoring recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31734103" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32409485" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32409485" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26844734" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antiepileptic Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26844734" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antiepileptic Drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24830765" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19170737" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clobazam in the treatment of Lennox-Gastaut syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21956725" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30870346" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Clobazam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30870346" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Clobazam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30870346" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Clobazam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31742671" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clonazepam monotherapy for treating people with newly diagnosed epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6424398" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411478" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34155624" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25528898" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784470" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784470" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23794036" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Drug interactions with the newer antiepileptic drugs (AEDs)--Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171423" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2545161" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200383" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8109904" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Felbamate: therapeutic range and other kinetic information</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8347179" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8243374" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606595" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955813" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The effect of felbamate on valproic acid disposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10448826" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12167463" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9599234" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801823" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898974" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33434292" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Gabapentin add-on treatment for drug-resistant focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898971" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898971" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9714500" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8088258" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. The US Gabapentin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20362757" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265421" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Gabapentin misuse, abuse and diversion: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28144823" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Abuse and Misuse of Pregabalin and Gabapentin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36069924" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32555114" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : In brief: Respiratory depression with gabapentinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36932941" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Non-opioid antinociceptive drugs : risk of respiratory depression and death related to concomitant use of gabapentinoids in addition to opioids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38224592" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Gabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease : A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19043448" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Lacosamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864845" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na(+) channel inactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864845" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na(+) channel inactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19183227" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132285" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635557" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33998660" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Lacosamide add-on therapy for focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22372628" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21555051" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Experience with lacosamide in a series of children with drug-resistant focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467791" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23143718" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266613" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24915838" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24915838" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30688870" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pharmacokinetic Variability and Clinical Use of Lacosamide in Children and Adolescents in Denmark and Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30086089" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Influence of Dose and Antiepileptic Comedication on Lacosamide Serum Concentrations in Patients With Epilepsy of Different Ages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22779776" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21056937" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970386" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21801173" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20570216" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37913565" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Neonatal Cardiac Arrest Following Lacosamide Treatment: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18248444" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344515" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937567" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27329345" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Lamotrigine add-on for drug-resistant partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077797" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18660469" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21838791" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16146436" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16981859" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16981856" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Contraception for women with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16981875" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17346247" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273825" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858461" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858461" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12136066" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Lamotrigine clearance during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304599" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030773" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157751" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effect of antiepileptic drug comedication on lamotrigine clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896946" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Pharmacokinetic interactions of the new antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896946" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pharmacokinetic interactions of the new antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17938371" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Lamotrigine extended-release as adjunctive therapy for partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17825077" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452293" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499755" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Predictors of Lamotrigine-associated rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26209753" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28005556" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Lamotrigine-Associated Hemophagocytic Lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28005556" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Lamotrigine-Associated Hemophagocytic Lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157917" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16686650" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846277" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22357718" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Lamotrigine and aseptic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15210974" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10611374" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436618" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Synaptic vesicle protein 2 enhances release probability at quiescent synapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20345933" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Alterations of intracerebralγ-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22292611" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Levetiracetam has an activity-dependent effect on inhibitory transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35393968" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Update on Antiseizure Medications 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972056" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11564123" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Efficacy of levetiracetam: a review of three pivotal clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14636332" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285535" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22050371" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19243423" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448575" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448575" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17625106" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915342" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Preliminary efficacy of levetiracetam in monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437904" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Levetiracetam monotherapy in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36184821" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Levetiracetam versus Oxcarbazepine as monotherapy in newly diagnosed focal epilepsy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28661008" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31627041" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29744790" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304598" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : A prospective analysis of the outcome of levetiracetam in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361605" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : The long term retention of levetiracetam in a large cohort of patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781837" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Levetiracetam for seizures after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17651416" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573925" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15679515" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Rapid onset of action of levetiracetam in refractory epilepsy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845730" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18505995" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Tolerability and efficacy of oral loading of levetiracetam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19175400" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279751" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Intravenous levetiracetam in children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886975" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326794" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19317886" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19777068" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19699156" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26930201" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Safety of Levetiracetam in Paediatrics: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31917143" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473557" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : The impact of levetiracetam on challenging behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18583196" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Positive and negative psychotropic effects of levetiracetam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547106" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33444989" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Aggression as psychiatric side effect of newer AEDs in patients with epilepsy: Cross-sectional study based on Buss-Perry Aggression Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18479387" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : The risk of paradoxical levetiracetam effect is increased in mentally retarded patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17825078" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Dramatic weight loss with levetiracetam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14563748" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Drug points: Weight loss associated with levetiracetam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14642998" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Tolerability of levetiracetam in elderly patients with CNS disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21204814" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424076" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Thrombocytopenia during levetiracetam therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15230717" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Levetiracetam-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15230717" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Levetiracetam-induced thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821367" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30350354" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275822" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Oxcarbazepine adjunctive therapy in infants and young children with partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132298" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Safety profile of oxcarbazepine: results from a prescription-event monitoring study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116024" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009219" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169036" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20235791" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913699" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970964" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970964" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22843280" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517103" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22905857" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23663001" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25878177" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26296511" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36150304" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Perampanel monotherapy for the treatment of epilepsy: Clinical trial and real-world evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25495693" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24867391" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27869305" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Analysis of falls in patients with epilepsy enrolled in the perampanel phase III randomized double-blind studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26140524" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27221398" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28511603" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28511603" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Clinical Experience With Perampanel for Refractory Pediatric Epilepsy in One Canadian Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2428283" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Phenytoin: mechanisms of its anticonvulsant action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099164" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1527539" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Bioavailability and dissolution of proprietary and generic formulations of phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1547767" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Double-blind randomized study comparing brand-name and generic phenytoin monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505173" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Lower phenytoin serum levels in persons switched from brand to generic phenytoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18637831" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18627414" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : The clinical impact of pharmacogenetics on the treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8621444" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11804619" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665421" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Pregabalin: a new anxiolytic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30688135" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Pregabalin as Adjunctive Treatment for Focal Onset Seizures in Pediatric Patients: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31287157" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Pregabalin add-on for drug-resistant focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380070" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Pregabalin: preliminary experience in intractable childhood epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21889410" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16146435" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21269291" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21314678" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15315511" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : Pregabalin pharmacology and its relevance to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11554426" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Brain microdialysis and PK/PD correlation of pregabalin in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222545" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740180" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : Pregabalin: as adjunctive treatment of partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692903" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699378" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194915" id="rid226" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>227 : Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320112" id="rid227" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>228 : The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422338" id="rid228" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>229 : Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18401024" id="rid229" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>230 : Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19162229" id="rid230" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>231 : Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185372" id="rid231" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>232 : First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070475" id="rid232" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>233 : Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21481742" id="rid233" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>234 : Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33179247" id="rid234" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>235 : Rufinamide add-on therapy for drug-resistant epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490053" id="rid235" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>236 : Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20887365" id="rid236" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>237 : A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503564" id="rid237" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>238 : Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19955344" id="rid238" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>239 : Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21463286" id="rid239" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>240 : The effects of stiripentol on GABA(A) receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390105" id="rid240" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>241 : Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390105" id="rid241" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>242 : Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11089822" id="rid242" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>243 : Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid243" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>244 : Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521067" id="rid244" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>245 : Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521067" id="rid245" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>246 : Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28521067" id="rid246" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>247 : Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23848835" id="rid247" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>248 : Stiripentol in Dravet syndrome: results of a retrospective U.S. study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299358" id="rid248" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>249 : (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500879" id="rid249" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>250 : Tiagabine add-on for drug-resistant partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24500879" id="rid250" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>251 : Tiagabine add-on for drug-resistant partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886974" id="rid251" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>252 : Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060592" id="rid252" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>253 : Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481654" id="rid253" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>254 : Seizure activity and off-label use of tiagabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442155" id="rid254" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>255 : Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16190934" id="rid255" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>256 : Status epilepticus and tiagabine therapy revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16190934" id="rid256" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>257 : Status epilepticus and tiagabine therapy revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24570033" id="rid257" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>258 : Topiramate add-on for drug-resistant partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17641254" id="rid258" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>259 : Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089937" id="rid259" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>260 : Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643672" id="rid260" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>261 : A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15857429" id="rid261" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>262 : Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19178563" id="rid262" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>263 : The role of titration schedule of topiramate for the development of depression in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823583" id="rid263" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>264 : Transient hypohidrosis induced by topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648001" id="rid264" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>265 : Hypohidrosis during topiramate treatment: a rare and reversible side effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22091778" id="rid265" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>266 : Genetic and environmental correlates of topiramate-induced cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753411" id="rid266" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>267 : Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985582" id="rid267" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>268 : Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650135" id="rid268" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>269 : Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894098" id="rid269" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>270 : Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030778" id="rid270" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>271 : Effect of topiramate on cognition in obese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148119" id="rid271" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>272 : Topiramate dose effects on cognition: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17561952" id="rid272" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>273 : The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24993246" id="rid273" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>274 : Effects of topiramate on language functions in newly diagnosed pediatric epileptic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962081" id="rid274" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>275 : Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894094" id="rid275" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>276 : How skeptical should we be about industry-sponsored studies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19563348" id="rid276" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>277 : Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12690085" id="rid277" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>278 : Predictors of weight loss in adults with topiramate-treated epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636070" id="rid278" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>279 : Long-term patterns of weight changes during topiramate therapy: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15648161" id="rid279" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>280 : [The key role of tubulointerstitium remodeling in progression of chronic renal diseases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442157" id="rid280" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>281 : Topiramate and metabolic acidosis in pediatric epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24811395" id="rid281" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>282 : Effect of Long-term Topiramate Therapy on Serum Bicarbonate and Potassium Levels in Adult Epileptic Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042105" id="rid282" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>283 : Topiramate-induced nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042105" id="rid283" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>284 : Topiramate-induced nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26158444" id="rid284" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>285 : Risk of angle-closure glaucoma with bupropion and topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19150415" id="rid285" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>286 : Presumed topiramate-induced maculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3086538" id="rid286" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>287 : Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3146860" id="rid287" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>288 : Experimental studies and controlled clinical testing of valproate and vigabatrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6791653" id="rid288" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>289 : Valproate induced changes in GABA metabolism at the subcellular level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12269861" id="rid289" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>290 : Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29243813" id="rid290" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>291 : Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28574586" id="rid291" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>292 : Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24523097" id="rid292" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>293 : Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24523097" id="rid293" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>294 : Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10980746" id="rid294" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>295 : Intravenous valproate is well tolerated in unstable patients with status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12536052" id="rid295" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>296 : Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505177" id="rid296" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>297 : Rapid infusion with valproate sodium is well tolerated in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668440" id="rid297" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>298 : Efficacy of rapid IV administration of valproic acid for status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17319914" id="rid298" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>299 : Safety of rapid intravenous loading of valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000309" id="rid299" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>300 : Comparative efficacy and safety of intravenous valproate and phenytoin in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160951" id="rid300" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>301 : Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565596" id="rid301" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>302 : Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19931165" id="rid302" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>303 : Metabolic alterations during valproic acid treatment: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682024" id="rid303" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>304 : The metabolic syndrome in overweight epileptic patients treated with valproic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32762394" id="rid304" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>305 : Sleep Architecture in Valproate-Induced Nocturnal Enuresis in Primary School and Preschool Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886976" id="rid305" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>306 : Valproate-associated coagulopathies are frequent and variable in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18031547" id="rid306" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>307 : Valproate-induced thrombocytopenia: a prospective monotherapy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31201069" id="rid307" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>308 : Valproic Acid-Induced Coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021925" id="rid308" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>309 : Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22114214" id="rid309" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>310 : Evaluation of subclinical hypothyroidism in ambulatory children with controlled epilepsy on valproate monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503558" id="rid310" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>311 : Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21204821" id="rid311" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>312 : Antiepileptic drugs, sex hormones, and PCOS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20304335" id="rid312" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>313 : Fanconi syndrome caused by valproic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201721" id="rid313" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>314 : The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797455" id="rid314" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>315 : Reversible parkinsonism and cognitive impairment with chronic valproate use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15111693" id="rid315" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>316 : Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16453247" id="rid316" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>317 : Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17115396" id="rid317" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>318 : Valproate-induced Parkinsonism in epilepsy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34004407" id="rid318" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>319 : Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3102998" id="rid319" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>320 : Valproic acid hepatic fatalities: a retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201699" id="rid320" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>321 : Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17322992" id="rid321" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>322 : Valproic acid-induced pancreatitis: 16 new cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015559" id="rid322" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>323 : The spectrum of valproic acid-associated pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440814" id="rid323" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>324 : Vigabatrin for refractory partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8956924" id="rid324" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>325 : Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406359" id="rid325" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>326 : Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575227" id="rid326" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>327 : Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20208475" id="rid327" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>328 : Vigabatrin (Sabril) for epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230067" id="rid328" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>329 : Vigabatrin: 2008 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11240600" id="rid329" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>330 : Visual field loss associated with vigabatrin: quantification and relation to dosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21246602" id="rid330" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>331 : Retinal nerve fiber layer thickness in vigabatrin-exposed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194884" id="rid331" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>332 : Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194884" id="rid332" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>333 : Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9022432" id="rid333" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>334 : Severe persistent visual field constriction associated with vigabatrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496247" id="rid334" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>335 : Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10599785" id="rid335" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>336 : Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10485552" id="rid336" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>337 : Symptomatic and asymptomatic visual loss in patients taking vigabatrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11463129" id="rid337" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>338 : Visual field defects with vigabatrin: epidemiology and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21070215" id="rid338" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>339 : Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19215279" id="rid339" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>340 : Visual fields at school-age in children treated with vigabatrin in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145415" id="rid340" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>341 : Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17635558" id="rid341" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>342 : Vigabatrin and epilepsy: lessons learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184224" id="rid342" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>343 : Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122710" id="rid343" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>344 : Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18783433" id="rid344" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>345 : Cerebral MRI abnormalities associated with vigabatrin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19054414" id="rid345" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>346 : Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20384718" id="rid346" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>347 : Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33432856" id="rid347" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>348 : Hippocampal Involvement With Vigabatrin-Related MRI Signal Abnormalities in Patients With Infantile Spasms: A Novel Finding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37690269" id="rid348" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>349 : Magnetic Resonance Imaging-Based Distribution and Reversibility of Lesions in Pediatric Vigabatrin-Related Brain Toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34786694" id="rid349" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>350 : Risk of vigabatrin-associated brain abnormalities on MRI: A retrospective and controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837461" id="rid350" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>351 : A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30335200" id="rid351" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>352 : Zonisamide add-on therapy for focal epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542880" id="rid352" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>353 : Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16647993" id="rid353" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>354 : Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20207201" id="rid354" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>355 : A prospective audit of adjunctive zonisamide in an everyday clinical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683226" id="rid355" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>356 : Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17319920" id="rid356" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>357 : Pharmacokinetics and drug interactions with zonisamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17945539" id="rid357" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>358 : Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20697103" id="rid358" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>359 : Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14762040" id="rid359" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>360 : The new antiepileptic drugs: scientific review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380624" id="rid360" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>361 : Hyponatremia from oxcarbazepine and carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8475694" id="rid361" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>362 : Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10881246" id="rid362" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>363 : Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11718497" id="rid363" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>364 : Oxcarbazepine in the treatment of epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697143" id="rid364" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>365 : Safety and tolerability of oxcarbazepine in elderly patients with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28542738" id="rid365" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>366 : Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24378204" id="rid366" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>367 : Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11551237" id="rid367" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>368 : Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22994856" id="rid368" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>369 : Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
